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ABSTRACT OF DISSERTATION

MULTIPLE PROTEINOPATHIES AND THEIR ROLE IN COGNITIVE
IMPAIRMENT AND NEURODEGENERATIVE DISEASES
Most age-related neurodegenerative disorders are associated with the aggregation
of misfolded and aberrant proteins. Alzheimer’s disease (AD) is one of the most common
neurodegenerative disorders and is highly prevalent in older adults. Neuropathologically,
AD is characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary
tangles (NFTs). Other misfolded proteins, including α-synuclein and transactive response
DNA-binding protein 43 (TDP-43), are also commonly observed in aged brains. Aberrant
α-synuclein has been associated with Parkinson's disease, Dementia with Lewy bodies,
and multiple system atrophy, whereas TDP-43 has been associated with multiple
neurological diseases, the most common of which was designated as limbic-predominant,
age-related TDP-43 encephalopathy (LATE). Each neurodegenerative disorder exhibits
aggregation of specific proteins, but very commonly there is an aggregation of multiple
proteinopathies.
The three studies in this dissertation are focused on the co-existence of multiple
proteinopathies. The primary data were drawn from the University of Kentucky
Alzheimer’s Disease research center (UK- ADRC), and additionally, for the second
study, we used data drawn from the National Alzheimer’s Coordinating Center (NACC).
While in the third study, the participants from UK-ADRC were linked to the Kentucky
Cancer Registry to obtain data regarding their history of cancer, along with additional
details such as cancer site, stage, and treatment received.
In the first study, “Prevalence and Clinical Phenotype of Quadruple Misfolded
Proteins in Older Adults,” using brain autopsy data from 375 older adults, quadruple
misfolded proteins (tau, amyloid-β, α-synuclein, and transactive response DNA-binding
protein 43) were commonly detected. Mild cognitive impairment transitioned to dementia
most rapidly for those with all four proteinopathies, which were present in 19% of
individuals with dementia. Overall, 12% of cases had QMP, while 38% had three
proteinopathies. Dementia frequency was highest among those with QMP (89%), and

participants with QMP had the lowest final mean MMSE (Mean=13.4, SD=9.8).
Adjusting for age and sex, ≥1 apolipoprotein ε4 (APOE ε4) allele was associated with
higher odds of QMP (OR=2.55; 95% CI, 1.16, 5.62, P= 0.02). The QMP group had both
the lowest probability of having normal MMSE, even 12 years before death and the
highest probability of having severe impairment on the MMSE. In the second study,
“Four common late-life cognitive trajectories patterns associate with replicable
underlying neuropathologies,” using group-based multi-trajectory models we found
evidence that there are distinct, common trajectories that define the end of life cognition.
The four distinct subgroups were determined by the shape of the trajectories using scores
from the Mini-Mental State Examination, Logical Memory, and Animal Naming tests
obtained in the last ten years of life; trajectories were labeled as No decline, Mild decline,
Moderate decline, and Accelerated decline. The Accelerated and the Moderate decline
groups were associated with lower age at death, lower educational attainment, higher
Braak NFT stage, and more frequent hippocampal sclerosis and TDP-43 proteinopathy.
Further, we validated the models using the NACC data. In the third study, “Cancer
history associates with a lower burden of dementia and Alzheimer’s-type neuropathology
in autopsied research volunteers.” History of cancer was reported in 190 (24.2%)
participants. The prevalence of ≥1 APOE ε4 allele was lower among the participants
with cancer history compared to cancer-free participants (32.6% vs 42.0%). Participants
with cancer history had significantly lower odds of MCI/dementia at the last UK-ADRC
visit (OR = 0.45; 95% CI, 0.31, 0.64; P < 0.0001), and had a reduced burden of AD
neuropathological changes in the brain. Additionally, the change in cognitive test scores
from baseline to the last available assessment showed relatively less decline in the
participants with a cancer history. The examination of AD-associated genes showed that
history of cancer was inversely associated with ≥1 APOE ε4 allele and higher odds of T
allele of SNP rs11136000 located in the CLU gene on chromosome 8.

KEYWORDS: Alzheimer’s Disease, Neurodegenerative diseases, Dementia, Multiple
proteinopathies, Neuropsychological tests, Cognitive trajectories.
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CHAPTER ONE
Introduction
Major neurodegenerative diseases can be determined by the presence of one of
four aggregated misfolded proteins each with distinct morphology and distribution.1 In a
healthy brain, these proteins are unstructured as a monomer, serving most likely as the
physiological form.2 In a disease state; the proteins namely amyloid-β (Aβ), tau, asynuclein, and transactive response DNA-binding protein 43 (TDP-43) turn pathological
and aggregate intracellularly, extracellularly, or both and are termed as “proteinopathies”.
However, proteinopathies also occur in individuals without any clinical presentation.3
These aggregates have the potential to disturb proteostasis, compromising cell function.4
Some of the etiological processes involved in misfolding are cellular aging, diseaserelated gene mutations, or proteotoxic stressors, like reactive oxygen species and toxins.4
Each of the pure proteinopathies define various neurodegenerative diseases, but most
commonly additional proteinopathies can accumulate as comorbid pathologies.3,5-7
Misfolded proteins
Tau
Tau proteins, ubiquitous in the adult brain, perform the function of stabilizing
microtubules of the neural cells. The tau protein binds to microtubules in axons, but in
certain neurodegenerative diseases, it is redistributed to the cell bodies.8 The tau proteins
that have become hyperphosphorylated insoluble aggregates are known as neurofibrillary
tangles (NFTs) (Figure 1.1). Neurodegenerative diseases characterized by the
accumulation of NFTs are known as “tauopathies”.8 Tauopathies encompass more than
20 clinicopathological entities; including Alzheimer’s disease (the most common
1

tauopathy), progressive supranuclear palsy, frontotemporal lobar degeneration (FTLDtau), corticobasal degeneration, Pick’s disease, chronic traumatic encephalopathy,
argyrophilic grain disease (AGD), and primary age-related tauopathy.9-12
NFT distribution in Alzheimer’s disease is defined by six Braak NFT stages (IVI).13 In Braak NFT stages I and II there is the involvement of the transentorhinal region
of the brain; in NFT stages III and IV there is also the involvement of limbic regions such
as the hippocampus, and in NFT stages V and VI there is widespread neocortical
involvement.13 Until recently, detection of tau deposition in the brain was only possible
from invasive techniques such as biopsy or autopsy. The recent development of tau PET
scan imaging provides a non-invasive detection of tau inclusions in the brain, which
could become a biomarker to discover tauopathies in the near future.14
Amyloid-beta
Aβ peptides derive from the larger amyloid precursor protein (APP), which are
cleaved by beta-secretase and gamma-secretase.15 The cleavage of APP occurs at position
40 or 42, which gives rise to two major variants: Aβ40 (Aβ ending at residue 40) and
Aβ42 (Aβ ending at residue 42).15 The cleaved portions aggregate to form flexible
soluble oligomers, which may exist in several forms and accumulate to form amyloid
plaques. Thus, these Aβ peptides are the main component of the extracellular amyloid
plaques found in the brains of people with Alzheimer's disease.15 Amyloid plaques can be
classified into two types: Neuritic plaques (NPs) and Diffuse plaques (DPs) (Figure 1.1).
The NPs are extracellular amyloid deposits invested by swollen, degenerating neurites.
Fibrillary polymers of the Aβ peptide comprise the structural core of NPs.16 DPs also
contain Aβ but lack the core and/or degenerating neurites.17 Cerebral amyloid angiopathy
2

(CAA) is a condition in which amyloid peptides build up in the walls of the cerebral
arteries.18 The Aβ and plaques in the arteries first occur in neocortical areas and then
expand into further brain regions.18

Figure 1.1: Photomicrographs of Alzheimer’s disease proteinopathies

A: Photomicrograph: shows
Immunohistochemical detection of
neurofibrillary degeneration using phosphotau antibody in the occipital cortex .9

B: Photomicrograph shows Aβ plaques
(reddish-brown,). Neurofibrillary tau
tangles (Black). Some of the Aβ plaques
contain aberrant tau protein pathology
(black marked by green arrows).19

Alpha-synuclein
Alpha-synuclein (α-synuclein) protein is encoded by the SNCA gene in humans.20
It is abundant in the brain, while smaller amounts are found in the heart, muscle, and
other tissues. Misfolded abnormal accumulations of insoluble fibrils α-synuclein are
characterized by Lewy bodies (Figure 1.2). The associated pathologies characterize
“synucleinopathies” and cause Lewy body spectrum diseases,3 like Parkinson’s disease
(PD), Dementia with Lewy bodies (DLB),20 and multiple system atrophy.6 DLB is the
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second most common form of degenerative dementia following AD in older adults21 and
frequently co-occurs with other proteinopathies.3,5,6,22,23
TDP-43
TDP-43 protein in humans is encoded by the TARDBP gene. Pathological TDP-43 forms
are observed as either neuronal cytoplasmic inclusions, neuronal intranuclear inclusions,
and/or dystrophic neurites (Figure 1.2).24 TDP-43 proteinopathy is associated with
frontotemporal lobar degeneration (FTLD-TDP), amyotrophic lateral sclerosis (ALS),
and more recently with limbic-predominant age-related TDP-43 encephalopathy (LATE)
in persons older than 80 years of age.25

Figure 1.2: Lewy body and TDP-43 proteinopathies

Lewy body

A: Photomicrograph: shows detection of high
concentrations of nitrated α-synuclein in the
Lewy bodies (shown with green arrow).9

B: Photomicrograph: shows detection of
intraneuronal phospho-TDP-43 inclusion
(red arrow) and a phospho-TDP-43 deposit
(green arrow) surrounding a capillary
(shown with blue arrows).25
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Mixed Pathologies
Aggregates of pathological/misfolded forms of tau, Aβ, α-synuclein, and TDP-43
in the brain combine in distinctive patterns in most neurodegenerative diseases.7
Although each misfolded protein is known to cause certain neurodegenerative diseases, in
many cases, there is an aggregation of multiple proteins). The existence of simultaneous
aggregation has been increasingly reported and is of serious concern as we try to develop
treatments for various neurodegenerative diseases, including AD. Treatment with
monotherapies targeting Aβ and tau in Alzheimer’s disease may not be helpful in treating
the disease. Misfolded proteins may co-exist in varying degrees across all of the different
neurodegenerative disorders26 and increase the odds of developing dementia,22 including
the clinical type of Alzheimer’s-type of dementia.25 Additionally, presence
cerebrovascular pathologies (infarcts, lacunes, arteriosclerosis, and atherosclerosis) are
prevalent in the brains of advanced aged subjects. Hippocampal sclerosis (HS)
pathologically characterized by neuronal cell loss and gliosis in the hippocampus
(unilaterally or bilaterally) has clinical signs and symptoms similar to AD and can occur
concurrently with other neurodegenerative diseases.25,27
Demographics, clinical presentation, and relevance of proteinopathies
The role of multiple proteinopathies and their association with clinical phenotypes
and neuropsychological profiles is complex and requires further understanding in
multiple aspects. Alzheimer’s disease, the most common form of dementia, is
characterized by progressive memory and cognitive decline. An estimated 5.8 million
Americans age 65 and older are living with Alzheimer’s dementia in 2020.1 By 2025, the
number is estimated to reach 7.1 million28 and 86,000 in Kentucky.29 Alzheimer’s is the
5

sixth-leading cause of death in the U.S, while in 2018 there were 1,674 deaths in
Kentucky attributable to the disease.28,29 While extensive research has been conducted in
understanding AD-type dementia, and other neurodegenerative diseases in terms of
diagnosis, biomarkers, imaging techniques, risk factors, and genetics, there are no
disease-modifying treatments or truly effective prevention methods. Diagnosis of
dementia, AD, and other neurodegenerative diseases involves clinical examination,
neuropsychological tests, brain-imaging studies using magnetic resonance imaging or
positron emission tomography, and detection of proteins in cerebrospinal fluid. Clinical
diagnosis of AD, which is the most common cause of dementia is classified into (1)
Probable AD dementia, (2) Possible AD dementia30 with a definite diagnosis established
only by neuropathologic examination on performing an autopsy.
Multiple non–modifiable risk factors such as aging, sex, and genetics increase
susceptibility to AD.31 Several modifiable risk factors that may be altered by healthy
lifestyle changes,31 such as cardiovascular diseases, diabetes, traumatic brain injuries, and
depression are also known to increase AD risk.31 However, the association between these
risk factors, dementia, and neuropathology may reflect a varied picture. Abner et al.32
reported that diabetes is associated with cerebrovascular but not AD-type pathology,
despite many large epidemiological studies reporting that diabetes increases the risk of
AD.33,34
Several prior studies using autopsy data have enhanced our understanding of the
association of risk factors with clinical AD, as well as the pathology present in the brain.
Interestingly, the association of cancer with AD is unique; prior research studies have
found strong evidence of an inverse association of cancer with AD.35-38 While most of the

6

studies have examined the association with clinically diagnosed AD or Dementia, to date
only two studies have used autopsy-confirmed brain diagnoses.39,40
Dissertation Outline
The purpose of the study is to expand on the understanding of the prevalence of
multiple proteinopathies, the associated clinical phenotype, and their role in cognitive
performance over time. In Chapter Two, the frequency and associated characteristics of
multiple proteinopathies, focusing on quadruple misfolded proteins (QMP: Tau, Amyloid
β, α-synuclein, TDP-43) among autopsied research volunteers were evaluated. Further,
demographic and neuropathological characteristics were described. The cognitive
diagnoses, duration of cognitive states, and longitudinal global cognition were evaluated
in the last 12 years of life. In Chapter Three, patterns of longitudinal cognitive status in
older adults using group-based multi-trajectory models were evaluated. Further,
predictors and proteinopathies associated with the cognitive trajectories indicating
cognitive status were evaluated. Additionally, random forest analyses were conducted to
evaluate the association of clinicopathological characteristics with cognitive trajectory
groups. We compared the results of the trajectory patterns and predictors to a larger study
population using National Alzheimer’s Coordinating Center (NACC) data. In Chapter
Four, we expanded the understanding of cancer vs. AD relationship using autopsy data to
evaluate whether the association of clinical AD diagnosis by prior studies is reflected by
AD neuropathology, as well as other neuropathological variables in data drawn from the
UK-ADRC community-based cohort. We applied causal inference methods (inverse
probability weighting) to investigate the relationship between cancer history,
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neuropathological features, and clinical diagnoses. The conclusion of the dissertation and
future research directions are discussed in Chapter Five.
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CHAPTER TWO
Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older
Adults
Abstract
Introduction: Quadruple misfolded proteins (tau neurofibrillary tangles, amyloid-β [Aβ],
α-synuclein, and transactive response DNA-binding protein 43 [TDP-43]) in the same
brain are relatively common in aging. However, the clinical presentation, associated
factors, frequency in community-based cohorts, genetic characteristics, and cognitive
trajectories associated with the quadruple misfolded proteins phenotype are not well
understood. To describe the quadruple misfolded proteins phenotype, including the
trajectories of global cognition, in an autopsy cohort.
Methods: This retrospective cohort study used brain autopsy data from the University of
Kentucky Alzheimer Disease Center (UK-ADRC) Brain Bank. Participants were
deceased individuals who were enrolled in a longitudinal community-based cohort study
of aging and dementia in central Kentucky conducted by the UK-ADRC. Included
participants were enrolled in the UK-ADRC cohort between January 1, 1989, and
December 31, 2017; aged 55 years or older at baseline; and followed up for a mean
duration of 10.4 years. The participants had Alzheimer disease pathology (tau and Aβ), αsynuclein, and TDP-43 data, along with Braak neurofibrillary tangle stage I to VI. Data
analysis was conducted between February 1, 2019, and September 30, 2019.
Results: Frequency of quadruple misfolded proteins was estimated, and proteinopathy
group characteristics and associations with global cognition were evaluated. Multinomial
logistic regression was used to estimate the association of proteinopathy group with
participant characteristics, including age at death, sex, and apolipoprotein ε4 (APOE ε4)
9

allele. Generalized estimating equations were used to estimate the probability of
obtaining Mini-Mental State Examination (MMSE) scores within the normal cognition
(27-30 points) and severe impairment (<13 points) ranges during the 12 years before
death. The final sample included 375 individuals (mean [SD] age at death, 86.9 [8.0]
years); 232 women [61.9%]). Quadruple misfolded proteins were detected in 41 of 214
individuals with dementia (19.2%). Overall, 46 individuals (12.3%) had quadruple
misfolded proteins, whereas 143 individuals (38.1%) had 3 proteinopathies. Dementia
frequency was highest among those with quadruple misfolded proteins (41 [89.1%]), and
participants with quadruple misfolded proteins had the lowest final mean (SD) MMSE
scores of 13.4 (9.8) points. Adjusting for age at death and sex, the APOE ε4 allele was
associated with higher odds of quadruple misfolded proteins (adjusted odds ratio (OR)=
2.55; 95% CI, 1.16, 5.62; P = .02). The quadruple misfolded proteins group had both the
lowest probability of obtaining MMSE scores in the normal cognition range, even 12
years before death and the highest probability of having MMSE scores in the severe
impairment range.
Conclusions: Quadruple misfolded proteins appear to be a common substrate for
cognitive impairment and to be associated with an aggressive course of disease that
typically ends with severe dementia. The prevalence of comorbid α-synuclein and TDP43 with Alzheimer disease pathology (tau and Aβ) may complicate efforts to identify
therapies to treat and prevent Alzheimer disease.
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Introduction
Amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFTs) define
Alzheimer disease neuropathological change (ADNC).9 Other misfolded proteins,
including α-synuclein and transactive response DNA-binding protein 43 (TDP-43),
also commonly occur in old age.24,26,41 Aberrant α-synuclein has been associated with
Parkinson disease, dementia with Lewy bodies, and multiple system atrophy,20
whereas TDP-43 has been associated with multiple neurological diseases,42 the most
common of which was designated as limbic-predominant, age-related TDP-43
encephalopathy.25,27
Neuropathological studies report that all 4 proteinopathies (Aβ, tau, α-synuclein,
and TDP-43) coexist in aged human brains.3,6,7,22,24,26,29,41,43-47 We use the term quadruple
misfolded proteins to describe this phenomenon. Other proteinopathies are associated
with increased dementia risk.22,46 For example, ADNC-associated cognitive impairment
has been associated with neocortical NFT density.9 The association of comorbid ADNC
and α-synuclein with ADNC is well documented6,48,49: compared with ADNC and
dementia with Lewy bodies pathology, pure dementia with Lewy bodies and ADNC were
associated with improved memory and global cognition.50,51 The TDP-43 proteinopathy
with ADNC also occurs5,24,25,52-54 and appears to be a factor in cognitive
impairment.5,24,42,52,54-56 In addition, TDP-43 is associated with memory loss and medial
temporal atrophy in persons with ADNC,57-59 and may preferentially change episodic and
working memory.55 Few studies have investigated the quadruple misfolded proteins
phenotype.3,24,26 Cognitive impairment is exacerbated by the presence of quadruple
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misfolded proteins compared with the presence of 1 to 3 proteinopathies.3,7,26 In this
cohort study, we identified the prevalence and characteristics of the quadruple misfolded
proteins phenotype in deceased research volunteers with brain autopsy data. We
evaluated demographic and neuropathological characteristics, cognitive diagnoses, and
global cognition trajectories in late life.
Methods
Study participants
We obtained brain autopsy data of long-term participants in a community-based
cohort study of aging and dementia in central Kentucky conducted by the University of
Kentucky Alzheimer Disease Research Center (UK-ADRC).16,60 These research
volunteers were recruited through community outreach, local press, or broadcast media;
enrolled between January 1, 1989, and December 31, 2017; aged 55 years or older at
baseline; followed up for a mean duration of 10.4 years; and autopsied. The UK-ADRC
Brain Bank that we used also contains autopsy data from a non–UK-ADRC cohort. We
included individuals with Braak NFT stage I or higher given the near-universal presence
of tau pathology in older adults and its association with cognition.9,61,62
We excluded individuals with Down syndrome or frontotemporal lobar
degeneration (FTLD); FTLD was excluded because of its rarity in the underlying
population despite its relevance to protein misfolding.25 Individuals with brain cancer
were also excluded. In addition, available data were needed on all proteinopathies under
study. Neuropathological assessments were performed with blinding of clinical
information. The University of Kentucky Institutional Review Board approved the study
procedures. Participants provided written informed consent.
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Cognitive Diagnoses and Evaluations
Cognitive diagnoses were based on annual examinations and were described
previously.63,64 Participant cognition was classified as normal, mild cognitive impairment
(MCI), impaired (but not MCI), or dementia. Normal cognition was defined as intact
functional ability and performance on neurocognitive tests within expected ranges for age
and years of education, and MCI was defined as objective cognitive impairment (score of
>1.5 SD below the expected mean) or cognitive complaint, intact global cognition, no or
minimal functional impairment, and no evidence of dementia.65 Impaired cognition was
defined according to the Uniform Data Set, a standard data protocol used by Alzheimer
disease centers.66 Participants with impaired cognition exhibited MCI features on clinical
examination, but neurodegenerative or cerebrovascular disease was not suspected in these
individuals. Standard criteria were used to determine dementia.67
Annual cognitive evaluations included the Mini-Mental State Examination
(MMSE).68 The MMSE scores, which have been consistently collected at UK-ADRC
since 1989, range from 0 to 30 points.68 For analysis, we classified MMSE scores as
follows: 27-30 points as normal cognition and 13 points or less as severe impairment.
These cutoff points were based on the guidelines published by Folstein et al68 and on the
cutoff points for severe dementia used in clinical trials.69 Indicators for MMSE score of
13 points or less were imputed for 24 participants with missing scores for more than 3
years before death and with a last observed MMSE score of 16 points or less, assuming
that the MMSE score decreased approximately 3 points per year.70
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Neuropathological Assessments
Brain autopsies were performed as described previously.16,71 Briefly, for autopsies
performed before 2012 (n = 203), Bielschowsky silver stains were used to detect neuritic
plaques (NPs) and diffuse plaques (DPs),and Gallyas silver stains72 were used to detect
NFTs in accordance with the 1997 National Institute on Aging and Reagan Institute
Working Group on Diagnostic Criteria for the Neuropathological Assessment of
Alzheimer’s Disease.73 For autopsies performed beginning in 2012 (n = 172),
immunohistochemical stains were used to detect Aβ deposits, and phospho–tau antibody
([PHF-1] a gift from Peter Davies, PhD, The Feinstein Institutes for Medical Research,
Manhasset, New York) was used to visualize NPs and NFTs (per the 2012 National
Institute on Aging–Alzheimer’s Association guidelines), with digital pathological
methods used for lesion detection and counting.74
Immunohistochemistry detection of α-synuclein aggregates, visualized with
mouse monoclonal antibody (clone KM51,Novocastra; Leica Biosystems),were assessed
using established diagnostic criteria.5 Evaluation of TDP-43 immuno-reactive inclusions
was performed on 5-μm-thick sections cut on slides (ProbeOn; Thermo Fisher Scientific).
Rat anti-phospho TDP-43 (clone 1D3; Millipore) was used after antigen retrieval in a
decloaking chamber and formic acid pretreatment. Secondary antibody reaction used the
avidin-biotin complex kit (Vectastain ABC Kit; Vector Laboratories). Details were
reported previously.5
Proteinopathy Groups
Participants were grouped on the basis of the presence of proteinopathies: Aβ, tau,
α-synuclein, and TDP-43.Tau was considered present when Braak NFT stage was I or
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higher, whereas Aβ was present when the CERAD (Consortium to Establish a Registry
for Alzheimer’s Disease) ratings for DPs or NPs were at least sparse.75 Meanwhile, αsynuclein was considered present if Lewy bodies were detected in the neocortex, medial
temporal lobe, or amygdala. In defining proteinopathy groups, we did not consider Lewy
bodies in the brainstem only (n = 7) as having α-synuclein. Previous work showed that
brainstem-only Lewy bodies were not associated with cognitive impairment.5 TDP-43
inclusion bodies were considered present for TDP-43 proteinopathy when detected in the
left or right hippocampus. Previous work suggested that amygdala-only TDP-43 was not
associated with odds of dementia or cognitive impairment.58 In addition, we divided
participants with pure ADNC into 2 groups according to Braak NFT stage (stage I to IV
and stage V to VI).
Participants were classified into 7 proteinopathy groups: (1) tau alone; (2) tau and
TDP-43; (3) tau Braak stage I to IV and Aβ; (4) tau Braak stage V to VI and Aβ; (5) tau,
Aβ, and α-synuclein; (6) tau, Aβ, and TDP-43; and (7) quadruple misfolded proteins (tau,
Aβ, TDP-43, and α-synuclein). Cerebrovascular pathology was not considered in
proteinopathy group definitions. We assessed gross diagnosis of atherosclerosis severity
(all vessels ≥50% vs <50% occluded), microscopic diagnosis of brain arteriolosclerosis
(moderate or severe vs none or mild), and brain infarcts (stage 0, none; stage 1,
microinfarcts or lacunar or large infarcts; and stage 2, both microinfarcts and lacunar or
large infarcts) within proteinopathy groups.3 In addition, the right and left hippocampi
were evaluated for hippocampal sclerosis.76 Presence of argyrophilic grain disease was
assessed in cornu ammonis, subiculum, and entorhinal regions.
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Covariates
Age at death, sex (reference group: male), years of education, and apolipoprotein
(APOE) ε4 allele were covariates of interest. The APOE (OMIM 107741) genotype was
converted to a dummy indicator for 1 or more ε4 alleles.
Statistical Analysis
Characteristics of participants by proteinopathy group were assessed with analysis
of variance or χ2 tests. Time in MCI and dementia states was calculated on the basis of
the dates of clinical diagnosis. When a participant transitioned to a new diagnosis
between annual visits, the diagnosis date was taken as the midpoint between the 2 visits.
Time in cognitive state that was consistent throughout follow-up (e.g. dementia at
baseline) was taken as the difference between the date of death and UK-ADRC study
enrollment date. We repeated the analyses on restricted cohort of participants who began
follow-up with normal cognition.
Multivariable multinomial logistic regression was used to estimate the association
between demographic characteristics and proteinopathy groups. Tau Braak stage I to IV
and Aβ was the largest proteinopathy group and served as the reference. Adjusted odds
ratios (AORs) with 95% CIs were obtained from the logistic regression model, which
included age at death, sex, and APOE ε4 allele indicator.
To evaluate the association of the proteinopathies with global cognition over time,
we used multivariable logistic regression with generalized estimating equations with a
first order autoregressive (AR[1]) working correlation structure. With this approach, we
estimated the probability that individuals in the proteinopathy groups obtained MMSE
scores within the normal range at each assessment in the 12 years before death (based on
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data availability), adjusting for age at death, sex, APOE ε4 allele, and years of education.
We used the same approach to estimate the probability that individuals would obtain
MMSE scores in the severe impairment range. The reference group was, again, tau Braak
stage I to IV and Aβ.
To assess potential misclassification owing to group definitions in the current
study, we examined amygdalar TDP-43 proteinopathy in a convenience sample of 47
individuals (of 234 [20.1%]) without hippocampal TDP-43. In addition, because the
definition of Aβ positivity could include individuals with low Aβ,we examined the joint
distribution of NP and DP ratings to ascertain the frequency of individuals with sparse
numbers of both NP and DP. All data were analyzed using SAS, version 9.4 (SAS
Institute Inc). Statistical significance was set at α = .05. Data analysis was conducted
between February 1, 2019, to September 30, 2019.
Results
The final sample included 375 individuals (Figure 2.1). The mean (SD) age at
death was 86.9 (8.0) years and ranged from 82.7 (10.3) years in the tau, Aβ, and αsynuclein proteinopathy group to 89.7 (6.7) years in the tau and TDP-43 group.
Participants were predominantly women (232 [61.9%]); were predominantly white
individuals (363 [96.8%]), which was consistent with the underlying population; and had
a mean (SD) 15.6 (3.1) years of education (Table 2.1).
Presence of multiple proteinopathies was common, with just 24 individuals
(6.4%) having tau alone (Figure 2.2). Two proteinopathies were detected in 162 of 375
individuals (43.2%), 3 proteinopathies in 143 individuals (38.1%), and quadruple
misfolded proteins in 46 individuals (12.3%). Overall, α-synuclein was present in 117
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individuals (31.2%), TDP-43 in 141 (37.6%), and tau and Aβ in 327 (87.2%). Individuals
with quadruple misfolded proteins had a higher frequency of Braak stage VI (23 [50.0%),
as did individuals with 3 proteinopathies (44 [approximately 30%]).
Dementia was diagnosed in 214 of 375 participants (57.1%), and 104 (27.7%)
participants retained normal cognition (Table 2.1). Dementia prevalence was highest in
the quadruple misfolded proteins group (41 [89.1%]), followed by tau, Aβ, and TDP-43
group (58 [81.7%]); tau Braak stage V to VI and Aβ group (41 [71.9%]); and tau, Aβ,
and α-synuclein group (44 [61.1%]). Among all participants with dementia (Figure 2.3),
quadruple misfolded proteins were present in 41 of 214 individuals (19.2%); tau, Aβ, and
TDP-43 in 58 individuals (27.1%); tau, Aβ, and α-synuclein in 44 individuals (20.6%);
and tau Braak stage V to VI and Aβ in 41 individuals (19.2%).
Among those with a final diagnosis of MCI (n = 45), none had quadruple
misfolded proteins (although 5 participants died with normal cognition), whereas 14
(31.1%) had tau Braak stage I to IV and Aβ; 11 (24.4%) had tau, Aβ, and α-synuclein; 7
(15.6%) had tau Braak stage V to VI and Aβ; and 6 (13.3%) had tau, Aβ, and TDP-43
(Figure 2.3). Among participants with an initial diagnosis of normal cognition (n = 228),
14 of 83 individuals (16.9%) with a final diagnosis of dementia had quadruple misfolded
proteins (Figure 2.4).
APOE ε4 allele was common in persons with quadruple misfolded proteins (23 of
46 [50.0%]), similar to those in the tau Braak stage V to VI and Aβ group (30 of 57
[52.6%]). In contrast, APOEε4 allele was observed in a single participant (4.2%) in the
tau alone group and in 3 of 24 participants (12.5%) in the tau and TDP-43 group. Mean
(SD) time spent in the MCI state was shortest among those in the quadruple misfolded
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proteins group (1.7 [0.6] years) (Table 2.1) and among those with initial normal
cognition (1.8 [0.6] years) (Table 2.2). This finding suggests a more aggressive disease
course for individuals with quadruple misfolded proteins (Figure 2.5).
Cerebrovascular burden (atherosclerosis, arteriolosclerosis, and infarcts) was
similar across groups (Table 2.1), although atherosclerosis was most prevalent in the
quadruple misfolded proteins group (30 of 46 [65.2%]) and in those who started followup with normal cognition (15 of 19 [79.0%]) (Table 2.1; Table 2.2). As expected,
hippocampal sclerosis was most common in participants with TDP-43. The highest
proportion of hippocampal sclerosis was in the quadruple misfolded proteins group (33
[71.7%) (Table 2.1). This finding may be relevant to a previous finding that more
clinically severe cases of limbic-predominant age-related TDP-43 encephalopathy–
neuropathological change are more likely to have hippocampal sclerosis pathology.25
The lowest final mean (SD) MMSE score was observed in the quadruple
misfolded proteins group (13.4 [9.8] points), which was significantly lower than in any
other group (P < .001). Although the final mean (SD) MMSE scores in the tau alone
group (26.6 [4.2] points) and tau Braak stage I to IV and Aβ group (26.2 [5.1] points)
indicated generally intact cognition at death, participants in all other groups had mean
MMSE scores lower than 21, indicating moderate to severe dementia (Table 2.1).
Among participants with initially normal cognition, the final mean (SD) MMSE score
was also lowest among those in the quadruple misfolded proteins group (18.9 [9.0]
points) (Table 2.4).
With a 5-year increase in age at death, participants were less likely to have
quadruple misfolded proteins (AOR= 0.82; 95% CI, 0.63,1.08; P = .15) or tau, Aβ, and α-
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synuclein (AOR=0.61; 95% CI, 0.48, 0.78; P < .001) compared with tau Braak stage I to
IV and Aβ (reference). APOE ε4 allele was associated with higher odds of having
quadruple misfolded proteins (AOR= 2.55; 95% CI, 1.16,5.62; P = .02); tau Braak stage
V to VI and Aβ (AOR= 3.45; 95% CI, 1.61,7.39; P < .001); and tau, Aβ, and TDP-43
(AOR= 2.34; 95%CI, 1.15, 4.77; P = .02). Sex was not significantly associated with the
proteinopathy groups (Table 2.5).
The estimated probabilities of obtaining MMSE scores categorized as normal
cognition and severely impaired cognition are shown in Figure 2.6. For example, 6 years
before death, the mean (SD) estimated probability of an MMSE score in the normal
cognition range (27-30 points) was lowest in the quadruple misfolded proteins group
(0.33 [0.24]), followed by tau, Aβ, and TDP-43 group (0.49 [0.12]); tau, Aβ, and αsynuclein group (0.57 [0.15]); and tau Braak stage V to VI and Aβ group (0.59 [0.16]; P
< .001 for all proteinopathy group β coefficients). Moreover, 6 years before death, the
mean [SD] probability of an MMSE score in the severe impairment range (≤13 points)
was highest in the quadruple misfolded proteins group (0.16 [0.10]; P < .001), followed
by tau, Aβ, and TDP-43 group (0.10 [0.05]; P < .001); tau, Aβ, and α-synuclein group
(0.07 [0.09]; P = .04); and tau Braak stage V to VI and Aβ group (0.05 [0.05]; P = .004).
To assess how proteinopathy definitions may have altered the results, we
performed 2 additional analyses. First, we assessed a convenience sample of 47
individuals without hippocampal TDP-43 proteinopathy, and TDP-43 was detected in the
amygdala of 19 participants (40.4%). By proteinopathy group of the sampled cases, TDP43 in the amygdala was detected in 12 of 23 participants (52.2%) in the tau, Aβ, and αsynuclein group; 3 of 8 participants (37.5%) in the tau Braak stage I to IV and Aβ group;
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4 of 13 participants (30.8%) in the tau Braak stage V to VI and Aβ group; and none in 3
participants assessed in the tau group. Twelve of 327 participants (3.7%) with Aβ
proteinopathy had only sparse numbers of both NPs and DPs: quadruple misfolded
proteins (n = 3); tau, Aβ, and α-synuclein (n = 1); and tau Braak stage I to IV and Aβ (n =
8).
Discussion
In this cohort study, we investigated quadruple misfolded proteins and other
proteinopathy combinations in a cohort of 375 deceased individuals with autopsy data. At
least 3 proteinopathies were observed in 50% of brains. Quadruple misfolded proteins
were observed in 19.2% of individuals with dementia, which was the same proportion of
participants with dementia who had pure ADNC with Braak stage V to VI. In addition,
quadruple misfolded proteins were associated with severe cognitive impairment at least
12 years before death.
Participants with 3 or more proteinopathies tended to have high Braak NFT stages
(V-VI). Higher Braak stage in these groups complicates the interpretation of the
association among risk factors, cognition, and comorbid brain pathologies because it
raises the question of which primary factor (the Braak stage or the number and
combination of proteinopathies) is associated with cognitive decline. Participants with 3
proteinopathies tended to have poorer global cognition earlier than with the presence of
only tau and Aβ and were likely to have higher Braak stages.
Previous studies have reported cognitive decline associated with the presence of
mixed pathologies,24,26,3,46,54 with study-to-study differences in methods and
proteinopathies,24,26,46,52 the assessment and inclusion of cerebrovascular
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pathologies,3,44,46 and hippocampal sclerosis.44,46 In the present sample, as in other
community-based cohorts,58 FTLD in old age was rare (with an estimated incidence of
8.9 of 100000 in individuals aged 60 to 69 years 77; no incidence data are available for
older age groups) and was not found in brains of individuals who began follow-up with
normal cognition.25 Individuals with FTLD-TDP with data in the UKADC Brain Bank
were recruited from a dementia clinic. We excluded 6 individuals with FTLD-TDP in the
study; none had the quadruple misfolded proteins phenotype. No discernible overlap in
any FTLD feature was observed in these individuals other than presence of TDP-43
proteinopathy, which is now detected in many different neurological diseases outside of
the amyotrophic lateral sclerosis–FTLD spectrum.77
Cognitive impairment was associated with quadruple misfolded proteins at
autopsy, with 89.1% of participants developing dementia and some experiencing
profound impairment (as measured by MMSE scores) up to 12 years before death. This
finding suggests that quadruple misfolded proteins occur before end-stage ADNC (i.e.,
before high Braak stage). Consistent with this hypothesis, the MCI-to-dementia transition
was, on average, fastest in the quadruple misfolded proteins group (Figure 3).
Estimation of the group cognitive trajectories was aided by the relatively long
follow-up (mean duration of 10.4 years). These data provide the basis for a novel
hypothesis that quadruple misfolded proteins have a more aggressive phenotype from the
early stages of the disease rather than accruing additional pathologies only after ADNC
has progressed to high levels. About 10% of these participants died with normal
cognition, and previous research has shown quadruple misfolded proteins were present in
persons with apparently normal cognition.3 In the present study, all individuals with
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quadruple misfolded proteins who had normal cognition at the last visit before death had
lower Braak NFT stages (I-III), had no APOE ε4 allele, and were predominantly male (4
of 5 participants). These individuals may represent an early stage of quadruple misfolded
proteins, but there are complexities: clinical presentation of proteinopathy combinations
may be cohort specific and depend on other currently unknown factors. Older cohorts that
survive into advanced old age, like those in the UK-ADRC study, may be more likely to
experience multiple proteinopathies than younger cohorts.
As previously described,3,26 APOE appeared to be associated with multiple
proteinopathies in this study, particularly those proteinopathy combinations including Aβ
plaques. Carriers of APOE ε4 allele not only had increased odds of tau and Aβ, an
expected result, but also had higher odds of tau, Aβ, and α-synuclein; tau, Aβ, and TDP43; and quadruple misfolded proteins. Unlike previous studies, this study did not find
evidence that the ε4 allele was associated with tau or TDP-43 in the absence of Aβ,56,78
but the sample size was relatively small.
The temporality of protein misfolding may play a clinically important and
differentiating role in disease progression. Autopsy data, although cross-sectional by
nature, are compatible with the hypothesis that Aβ aggregates precede, and perhaps
stimulate or exacerbate, the widespread misfolding of tau, TDP-43, and α-synuclein.13
These results suggest that TDP-43 pathology may be associated with poor global
cognition.
Limitations
This study has limitations. The cohort comprised primarily older adult, white, and
well-educated participants, which limit generalizability of the findings. Some studies
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have reported that black 79,80 and Hispanic 80 persons are more likely to have mixed
ADNC. Furthermore, although the sample size was relatively large for an autopsy-based
study, it underpowered some intergroup comparisons. The sample size also limited our
ability to assess associations with other participant characteristics, such as medical
history and environmental risk factors. In particular, the association of traumatic brain
injury with quadruple misfolded proteins and multiple proteinopathies needs to be
addressed in future research.
We did not use data on TDP-43 pathology in brain regions other than the
hippocampus. In a future study, we will examine the role of limbic-predominant, agerelated TDP-43 encephalopathy neuropathological change stages 1 and 3 in the disease
course of individuals with mixed pathology. The convenience sample analyses suggest
that 30% to 40%of individuals without hippocampal TDP-43 pathology may have TDP43 in the amygdala, although the amygdalar TDP-43 pathology was often sparse.
However, the convenience sample was about 5 years younger than the overall cohort but
had a higher proportion of Braak stage V (similar in all other characteristics), which
suggests that the true proportion of participants with amygdalar TDP-43 but without
hippocampal TDP-43 is higher than the estimate. Furthermore, the definition of Aβ
positivity could include individuals with little amyloid, and we did not include
quantitative measures of amyloid in the analyses. The analyses showed few individuals in
any group with lowβ; thus, we believe that adjusting for quantitative Aβ in the models
would not change the results meaningfully.
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Conclusions
The presence of multiple proteinopathies, particularly the quadruple misfolded
proteins phenotype, appeared to have been associated with the cognitive decline in
deceased individuals who participated in a longitudinal community-based study at the
UK-ADRC. Most individuals who had quadruple misfolded proteins had dementia, and
none died with MCI. These observations have potentially significant implications for
clinical practice and public health, given that strategies to prevent or manage AD
dementia may be complicated by the unrecognized presence of multiple additional
neuropathologies.
Funding
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Figure 2.1: Flow diagram included cases

Total Brain Bank Autopsies
n=884

•
•
•
•
•

Exclusions
No TDP-43 neuropathology data (n=449)
Braak stage 0 (n=34)
FTLD (n=13)
Rare Dementia Syndrome (n=9)
Down syndrome (n=4)

Cases included
n= 375

Abbreviation: TDP-43, transactive response DNA-binding protein of 43 kDa;
FTLD, frontotemporal lobar degeneration
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Table 2.1: Proteinopathy case group characteristics
TauBraak VVI + Aβ
n=57
86.1 (7.9)
37 (64.9)

Tau
+TDP-43
n=24
89.7 (6.7)
18 (75.0)

Tau+Aβ
+α-Syn
n=72
82.7 (10.3)
41 (56.9)

Tau+Aβ
+TDP-43
n=71
89.2 (5.6)
44 (61.9)

QMP
n=46
86.3 (7.6)
28 (60.9)

Age at death, y
Female sex

Overall
n=375
86.9 (8.0)
232 (61.9)

Tau
n=24
87.0 (6.6)
16 (66.7)

TauBraak IIV+Aβ
n=81
88.7 (7.0)
48 (59.3)

White race

363 (96.8)

24 (100.0)

78 (96.3)

56 (96.3)

23 (95.8)

69 (95.8)

70 (98.6)

42 (93.5)

Education, y

15.6 (3.1)

15.1 (2.6)

16.0 (2.9)

14.9 (3.5)

16.2 (2.3)

16.0 (2.9)

15.4 (3.4)

15.3 (3.4)

APOE ε4 (≥1 allele)
MMSE

137 (36.5)
20.0 (9.7)

1 (4.2)
26.6 (4.2)

21 (25.9)
26.2 (5.1)

30 (52.6)
17.4 (9.3)

3 (12.5)
20.5 (8.9)

30 (41.7)
19.4 (10.1)

29 (40.8)
15.7 (10.2)

23 (50.0)
13.4 (9.8)

Last Clinical Dx
Normal
Impaired
MCI
Demented

104 (27.7)
10 (2.7)
45 (12.0)
214 (57.1)

16 (66.7)
3 (12.5)
2 (8.3)
3 (12.5)

48 (59.3)
3 (3.7)
14 (17.3)
16 (19.8)

7 (12.3)
1 (1.8)
7 (12.3)
41 (71.9)

8 (33.3)
0
5 (20.8)
11 (45.8)

14 (19.4)
3 (4.2)
11 (15.3)
44 (61.1)

6 (8.5)
0
6 (8.5)
58 (81.7)

5 (10.9)
0
0
41 (89.1)

Braak stage
I
II
III
IV
V
VI

35 (9.3)
77 (20.5)
43 (11.5)
36 (9.6)
87 (23.2)
97 (25.9)

10 (41.7)
10 (41.7)
2 (8.3)
2 (8.3)
0
0

0
40 (49.4)
23 (28.4)
18 (22.2)
-

27 (47.4)
30 (52.6)

8 (33.3)
11 (45.8)
4 (16.7)
1 (4.2)
0
0

13 (18.1)
9 (12.5)
5 (6.9)
4 (5.6)
20 (27.8)
21 (29.2)

3 (4.2)
3 (4.2)
4 (5.6)
7 (9.8)
31 (43.7)
23 (32.4)

1 (2.2)
4 (8.7)
5 (10.9)
4 (8.7)
9 (19.6)
23 (50.0)

Atherosclerosis
<50% occluded
≥50% occluded

149 (39.7)
222 (59.2)

12 (50.0)
12 (50.0)

29 (35.8)
52 (64.2)

27 (47.4)
30 (52.6)

11(45.8)
13 (54.2)

31 (43.1)
40 (55.6)

25 (35.2)
45 (63.4)

14 (30.4)
30 (65.2)

Arteriolosclerosis
None/Mild
Moderate/Severe

238 (64.5)
92 (24.5)

17 (70.8)
5 (20.8)

49 (60.5)
24 (29.6)

36 (63.2)
12 (21.1)

15 (62.5)
6 (25.0)

52 (72.2)
18 (25.0)

38 (53.5)
16 (22.5)

31 (67.4)
11 (23.9)

Variable
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Infarcts
Stage 0
Stage 1
Stage 2

254 (67.7)
66 (17.6)
55 (14.7)

15 (62.5)
4 (16.7)
5 (20.8)

48 (59.3)
19 (23.4)
14 (17.3)

40 (70.2)
6 (10.5)
11 (19.3)

13 (54.2)
5 (20.8)
6 (25.0)

60 (83.3)
8 (11.1)
4 (5.6)

45 (63.4)
16 (22.5)
10 (14.1)

33 (71.7)
8 (17.4)
9 (10.9)

Time in state, y
MCI
Dementia

2.9 (2.4)
5.3 (3.4)

4.1 (3.6)
8.9 (2.9)

3.0 (2.4)
4.7 (2.8)

2.9 (2.0)
3.9 (2.8)

3.0 (1.9)
4.9 (2.5)

2.9 (3.2)
5.3 (4.1)

3.0 (2.4)
5.8 (3.3)

1.7 (0.6)
6.2 (3.5)

Data are mean (SD) or n (%). Abbreviation: SD, standard deviation; MMSE, Mini-Mental State Examination; QMP, quadruple
misfolded proteins; Aβ, Amyloid Beta; α-Syn, α-Synuclein; TDP-43, transactive response DNA-binding protein of 43 kDa;
APOE ε4, Apolipoprotein ε4 allele; Dx, Diagnosis; Stage 0, none; Stage 1, microinfarcts or lacunar/large infarcts; Stage 2,
both microinfarcts or lacunar/large infarcts; Missing data information is reported in Table 2.3 and Table 2.4
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Table 2.2: Participant Characteristics by Proteinopathy Among Participants Who Started as Cognitively Normal at Baseline
(n=228)
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Variable
Age at death, y
Age on onset (MCI)
Age of onset,
Dementia
Female sex
White race
Education, y
APOE ε4 (present)
Final MMSE
Last Clinical Dx
Normal
Impaired/Other
MCI
Demented
Braak NFT stage
I
II
III
IV
V
VI
Atherosclerosis
<50% occluded
≥50% occluded
Arteriolosclerosis
None/Mild
Moderate/Severe
Infarcts
Stage 0
Stage 1

Overall
n=228
89.1 (6.4)
85.1 (6.7)

Tau
n=20
85.6 (6.1)
82.6 (3.7)

TauBraak IIIV+ Aβ
n= 75
88.8 (6.5)
87.1 (5.6)

86.1 (6.9)
149 (65.4)
224 (98.3)
16.1 (2.6)
73 (32.0)
23.7 (7.8)

82.0 (NA)
13 (65.0)
20(100.0)
15.2 (2.7)
1 (5.0)
27.9 (2.2)

88.7 (5.4)
44 (58.7)
73 (97.3)
15.9 (2.5)
21 (28.0)
26.7 (4.5)

85.5 (8.6)
20 (66.7)
30 (100.0)
16.0 (3.0)
17 (56.7)
21.2 (8.6)

88.5 (6.2)
15 (88.2)
16 (94.2)
16.7 (2.4)
3 (17.7)
22.2 (9.1)

81.7 (7.0)
24 (75.0)
31 (96.9)
15.9 (2.7)
13 (40.6)
23.7 (8.3)

88.3 (4.3)
21 (60.0)
35 (100.0)
16.5 (2.6)
12 (34.3)
19.6 (9.7)

83.6 (8.4)
12 (63.2)
19(100.0)
16.4 (2.3)
6 (31.6)
18.9 (9.0)

104 (45.6)
6 (2.6)
35 (15.4)
83 (36.4)

16 (80.0)
1 (5.0)
2 (10.0)
1 (5.0)

48 (64.0)
3 (4.0)
12 (16.0)
12 (16.0)

7 (23.3)
1 (3.3)
7 (23.3)
15 (50.0)

6 (35.3)
0
3 (17.7)
6 (47.1)

14 (43.8)
1 (3.1)
6 (18.8)
11 (34.4)

6 (17.1)
0
5 (14.3)
24 (68.6)

5 (26.3)
0
0
14 (73.7)

17 (7.5)
65 (28.5)
40 (17.5)
30 (13.2)
54 (23.7)
22 (9.6))

7 (35.0)
9 (45.0)
2 (10.0)
2 (10.0)
0
0

0
37 (49.3)
23 (30.7)
15 (20.0)
-

20 (66.7)
10 (33.3)

4 (23.5)
8 (47.1)
4 (23.5)
1 (5.9)
0
0

4 (12.5)
6 (18.8)
4 (12.5)
4 (12.5)
10 (31.2)
4 (12.5)

1 (2.9)
2 (5.7)
3 (8.6)
6 (17.1)
20 (57.1)
3 (8.6)

1 (5.3)
3 (15.8)
4 (21.1)
2 (10.5)
4 (21.1)
5 (26.3)

86 (37.7)
142 (62.3)

12 (60.0)
8 (40.0)

28 (37.3)
47 (62.7)

12 (40.0)
18 (60.0)

8 (47.1)
9 (52.9)

12 (37.5)
20 (62.5)

10 (28.6)
25 (71.4)

4 (21.1)
15 (79.0)

145 (63.6)
60 (26.3)

16 (80.0)
2 (10.0)

46 (61.3)
21 (28.0)

20 (66.7)
6 (20.0)

10 (58.8)
5 (29.4)

21 (65.6)
9 (28.1)

22 (62.9)
9 (25.7)

10 (52.6)
8 (42.1)

114 (50.0)
78 (34.2)

12 (63.2)
2 (10.5)

39 (51.3)
21 (27.6)

11 (36.7)
11 (36.7)

8 (47.1)
8 (47.1)

19 (59.4)
11(34.4)

15 (42.9)
18 (51.4)

10 (52.6)
7 (36.8)

TauBraak V-VI
+Aβ
n= 30
89.0 (6.9)
84.2 (7.2)

Tau+TDP43
n= 17
90.9 (7.0)
89.7 (4.7)

Tau Aβ
+ α-Syn
n= 32
87.5 (6.5)
79.6 (7.9)

Tau+Aβ +
TDP-43
n=35
91.7 (4.0)
86.8 (3.8)

QMP
n= 19
90.2 (6.2)
82.1 (9.4)

Stage 2
HS (present)
AGD (present)
Mean time in state, y
MCI
Dementia

36 (15.8)

5 (26.3)

16 (21.1)

8 (26.7)

1 (5.9)

2 (6.3)

2 (5.7)

2 (10.5)

44 (19.3)
35 (15.3)

0
4 (20.0)

1 (1.3)
14 (18.7)

1 (3.3)
3 (10.0)

8 (47.1)
2 (11.8)

2 (6.3)
1 (3.1)

18 (51.4)
8 (22.9)

14 (73.7)
3 (15.8)

2.9 (2.0)
4.9 (3.1)

3.1 (3.1)
7.1 (NA)

3.0 ( 2.4)
3.9 (2.4)

3.0 (2.0)
4.6 (3.5)

3.3 (1.7)
4.9 (1.6)

2.7 (1.9)
6.2 (3.9)

3.1 (2.1)
4.8 (2.7)

1.8 (0.6)
5.7 (3.8)

Data are mean (SD) or n (%). y, years; MMSE, Mini-Mental State Examination; ; QMP, quadruple misfolded proteins; Aβ,
Amyloid Beta; α-Syn, α-Synuclein; TDP-43, transactive response DNA-binding protein of 43 kDa; APOE ε4 - Apolipoprotein
ε4 allele; Dx, Diagnosis; MCI, Mild cognitive impairment; NA, SD could not be calculated, only one participant in the cell.;
Stage 0, No infarcts; Stage 1, microinfarcts or lacunar/large infarcts; Stage 2,both microinfarcts and lacunar/larger infarcts;
HS-Hippocampal Sclerosis; ; AGD- Argyrophilic grain disease. Missing data information can be found in Table 2.3 and 2.4.
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Figure 2.2. Distribution of Proteinopathy Groups Among Participants
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20
10
0

21.6
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Abbreviation: QMP, quadruple misfolded proteins; Aβ, Amyloid Beta; α-Syn, αSynuclein; TDP-43, transactive response DNA-binding protein of 43 kDa.
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Figure 2.3. Distribution of Proteinopathy Groups Among Participants With Dementia
and Participants With Mild Cognitive Impairment (MCI) Proximate to Death

Abbreviations: Aβ indicates amyloid-β; αSyn, α-synuclein; QMP, quadruple misfolded
protein; and TDP-43, transactive response DNA-binding protein 43.
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Figure 2.4: Distribution of Proteinopathy Groups Among Participants with Dementia and
Participants With Mild Cognitive Impairment (MCI) Proximate to Death Who Started as
Cognitively Normal at Baseline (n=228)
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14.3
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Tau alone

8.6
5.7
MCI (n=35)

Abbreviation: MCI, Mild cognitive impairment; QMP, quadruple misfolded proteins; Aβ,
Amyloid Beta; α-Syn, α-Synuclein; TDP-43, transactive response DNA binding protein
43 kDa.
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Figure 2.5. Hypothesized Patterns of Late-Life Cognitive Decline Associated With
Specific Proteinopathies

Quadruple misfolded protein (QMP) is distinguished by early decline in cognition (A),
fast transition through mild cognitive impairment of approximately 1.7 years (B), and
long duration of severely abnormal cognition (C).
Abbreviation: Aβ indicates amyloid-β; ADNC, Alzheimer disease neuropathological
change; αSyn, α-synuclein; LATE-NC, limbic-predominant, age-related TDP-43
encephalopathy neuropathological change; and TDP-43, transactive response DNAbinding protein 43.
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Figure 2.6 Mean Estimated Probabilities of Obtaining Normal or Severely Impaired Mini-Mental State Examination
(MMSE) Score Ranges in the 12 Years Before Death
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Abbreviation: Aβ indicates amyloid-β; αSyn, α-synuclein; QMP, quadruple misfolded protein; and TDP-43, transactive
response DNA-binding protein 43.

Table 2.3: Frequency of missing data in all participants (n=375)
Variable

Overall
n=375
Education
7
APOE ε4 (present) 19
MMSE
48
Last clinical Dx
2
Atherosclerosis
4
Arteriolosclerosis 45
HS
4
AGD
9

Tau
n=24
0
0
1
0
0
2
1
0

TauBraak IIV + Aβ
n=81
1
2
4
1
0
8
0
3

TauBraak VVI + Aβ
n=57
1
5
10
0
0
9
0
2

Tau
+ TDP-43
n=24
0
1
1
0
0
3
0
1

Tau + Aβ
+ α-Syn
n=72
1
5
11
0
1
2
1
0

Tau + Aβ
+ TDP-43
n=71
1
5
10
1
1
17
2
2

QMP
n=46
3
1
11
0
2
4
0
1
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Table 2.4: Frequency of Missing Data in all Participants Who Started as Cognitively Normal at Baseline (n=228)
Variable
Education
APOE ε4 (present)
MMSE
Arteriolosclerosis
HS
AGD

Overall
n=228
3
2
18
23
2
6

Tau
n=20
0
0
0
2
1
0

Tau Braak IIV + Aβ
n= 75
1
2
3
8
0
3

TauBraak VVI + Aβ
n= 30
0
0
4
4
0
2

Tau
+TDP-43
n= 17
0
0
1
2
0
0

Tau + Aβ
+ α-Syn
n= 32
1
0
6
2
1
0

Tau +Aβ +
TDP-43
n=35
0
0
2
4
0
1

QMP
n= 19
1
0
2
1
0
0

Abbreviation: MMSE, Mini-Mental State Examination; QMP, quadruple misfolded proteins; Aβ, Amyloid Beta; α-Syn, αSynuclein; TDP-43, transactive response DNA-binding protein of 43 kDa; APOE ε4 - Apolipoprotein ε4 allele; Dx, Diagnosis;
HS-Hippocampal Sclerosis; ; AGD- Argyrophilic grain disease; Variables not listed here are fully observed

Table 2.5: Adjusted odds ratios and 95% confidence intervals for odds of proteinopathy
case group membership relative to Tau (Braak I-IV) + Aβ
Variable
Age at death
(5 year increase)

Female sex

APOE ε4 allele ≥1 vs 0

Proteinopathy groups
Tau
TauBraak V-VI + Aβ
Tau + TDP-43
Tau + Aβ + α-Syn
Tau+ Aβ + TDP-43
QMP
Tau
TauBraak V-VI + Aβ
Tau + TDP-43
Tau + Aβ + α-Syn
Tau+ Aβ + TDP-43
QMP
Tau
TauBraak V-VI + Aβ
Tau + TDP-43
Tau + Aβ + α-Syn
Tau+ Aβ + TDP-43
QMP

Adjusted OR (95% CI)
0.71 (0.51-1.00)
0.85 (0.66-1.11)
1.02 (0.69-1.49)
0.61 (0.48-0.78)
1.15 (0.89-1.50)
0.82 (0.63-1.08)
1.65 (0.60-4.51)
1.48 (0.69-3.15)
1.87 (0.65-5.38)
1.41 (0.70-2.87)
1.00 (0.50-1.99)
1.18 (0.55-2.57)
0.10 (0.01-0.77)
3.45 (1.61-7.39)
0.43 (0.11-1.62)
1.53 (0.73-3.19)
2.34 (1.15-4.77)
2.55 (1.16-5.62)

Results are from multinomial logistic regression with age, sex and APOE ε4 as
covariates. OR, odds ratio; CI, confidence interval; QMP, quadruple misfolded proteins;
Aβ, Amyloid Beta; α-Syn, α-Synuclein; TDP-43, transactive response DNA-binding
protein of 43 kDa; APOE ε4 - Apolipoprotein ε4 allele. 19 participants were excluded
from this analysis due to missing data (Table 2.3).
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CHAPTER THREE
Four common late-life cognitive trajectories patterns associate with replicable
underlying neuropathologies
Abstract
Background: Late-life cognitive function is heterogeneous, ranging from no decline to
severe dementia. Prior studies of cognitive trajectories have tended to focus on a single
measure of global cognition or individual tests scores, rather than considering
longitudinal performance on multiple tests simultaneously. The current study aimed to
examine cognitive trajectories from two independent datasets to assess whether similar
patterns might describe longitudinal cognition in the decade preceding death, as well as
what participant characteristics were associated with trajectory membership.
Materials and Methods: Data were drawn from autopsied longitudinally followed
participants of two cohorts (total N=1346), a community-based cohort at the University
of Kentucky Alzheimer’s Disease Research Center (UK-ADRC) and National
Alzheimer’s Coordinating Center (NACC). We used group-based multi-trajectory models
(GBMTM) to identify cognitive trajectories over the decade before death using MiniMental State Exam, Logical Memory-Immediate, and Animal Naming performance.
Multinomial logistic and Random Forest (RF) analyses assessed characteristics
associated with trajectory groups.
Results: There were 365 participants included from UK-ADRC and 981 participants
from NACC. GBMTM identified four similar cognitive trajectories in each dataset. In
multinomial models, death age, Braak NFT stage, TDP-43, and α-synuclein were
associated with declining trajectories. RF results suggested most important trajectory
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predictors were Braak NFT stage, cerebral atrophy, death age, and brain weight. Multiple
pathologies were most common in trajectories with moderate or accelerated decline.
Conclusion: Cognitive trajectories are associated strongly with neuropathology,
particularly Braak NFT stage. The high frequency of multiple pathologies in trajectories
with cognitive decline suggests dementia treatment and prevention efforts must consider
multiple diseases simultaneously.
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Introduction
Cognitive impairment and dementia are associated with multiple brain
pathologies in elderly persons,5,23,26 particularly accumulation of tau neurofibrillary
tangles (NFTs) with amyloid-β (Aβ) plaques, α-synuclein, and TAR-DNA binding
protein 43 kDa (TDP-43).5,26 Additionally, infarctions and other cerebrovascular
pathologies are prevalent and deleterious for cognition.5,32 Although prior studies have
characterized cognitive status before death related to specific neurodegenerative diseases,
fewer studies have evaluated trajectories of cognitive decline in the presence of multiple
pathologies.47,81-84
Group-based trajectory models (GBTM) are a specialized application of finite
mixture modeling developed to identify longitudinal patterns and distinctive
trajectories.85,86 GBTM allows visualization of cognitive trajectories, as well as
classification of similar individuals into clinically meaningful groups.85 Group-based
multi-trajectory modeling (GBMTM), an extension of GBTM, identifies shared
trajectories across multiple outcomes of interest 87 (e.g., cognitive function as measured
by multiple cognitive tests). Prior studies seeking to identify distinct patterns of
cognition82,88-91 have relied on either cognitive test scores that are examined one test at a
time,88 or on a summary global cognition score derived from all tests.83 Here, we used
GBMTM to identify cognitive trajectories based simultaneously on three cognitive tests,
representing global cognition, episodic memory, and category fluency.
Autopsied research volunteers from the University of Kentucky Alzheimer’s
Disease Research Center (UK-ADRC), as well as a separate sample of autopsied research
volunteers from various ADRCs contributing data to the National Alzheimer’s
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Coordinating Center (NACC) Neuropathology Data Set,66 were included in the current
study. The National Institute on Aging funds all ADRCs. While UK-ADRC research
participants were mostly recruited from the community, many ADRCs recruit from
memory disorders clinics. We examined cognitive trajectories to assess whether similar
patterns might describe longitudinal cognition in the decade preceding death, as well as
what characteristics were associated with trajectory group membership.
Methods
Study participants (UK-ADRC)
Data were drawn from the community-based cohort study of aging and dementia
at the UK-ADRC.60 Included participants were enrolled from 1989-2017 and were ≥ age
55 years at baseline (the usual age of eligibility for this cohort is age 70 and over).
Inclusion criteria were available cognitive test data (see “Neuropsychological battery test
scores”), Alzheimer’s disease (AD) pathologies (Braak NFT stage, Aβ plaque rating), αsynuclein, and TDP-43 proteinopathies. We excluded participants with brain cancer,
Down syndrome, frontotemporal lobar degeneration, and other rare dementia syndromes
(given small numbers of cases for comparison between the datasets). FTLD cases are rare
in old age, as were in the present sample, as in other community-based cohorts.58,92
Study participants (NACC)
Data were drawn from the NACC Uniform Data Set (UDS), and Neuropathology
Data Set (NP), comprising participants enrolled at ADRCs throughout the United States
(UK-ADRC). NACC maintains multicenter databases comprising standardized ADRC
data protocols. Twenty-six ADRCs contributed data to both NACC UDS and NP through
the September 2019 data freeze (https://www.alz.washington.edu/), when our data were
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extracted. To generate an independent dataset comparable to UK-ADRC, we included
participants based on the same criteria as above.
Neuropsychological battery test scores
At each clinical evaluation, participants were administered a battery of cognitive
tests. To study their cognitive trajectories, we included tests measuring global cognition
(Mini-Mental State Examination; MMSE),68 episodic memory (Wechsler Memory ScaleRevised [WMS-R] Logical Memory Story A),93 and category verbal fluency (Animal
Naming Test)94 as these were consistently measured across all participants.
The MMSE is frequently used to evaluate global cognition in older adults; scores
range from 0-30.68 Logical Memory measures the total number of story units recalled
verbatim from a narrated short story; scores range from 0-25.93 In the Animal Naming
Test, participants name as many animals as they can in 60 seconds;95 observed scores
ranged from 0-41 (UK-ADRC) and 0-52 (NACC). We considered MMSE <27, Logical
Memory <9, and Animal Naming <12 as abnormal scores, based on the baseline
performance among the cognitively normal NACC study population.94
In March 2015, the NACC UDS changed to Version 3.0, wherein the MMSE was
replaced by the Montreal Cognitive Assessment (MoCA),96 and WMS-R Logical
Memory IA-Immediate was replaced by Craft Story 21 Recall-Immediate.97 NACC
provides harmonized data crosswalks to researchers that bridge these scores.97 Monsell et
al. reported that the new tests (Version 3.0) were well correlated with the previous tests
(Version 2.0) 97. Hence, we used harmonized scores for all NACC participants from
March 2015 onwards. UK-ADRC continued to obtain the MMSE, and so those scores
were used, while the harmonized Logical Memory scores were used.
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Cognitive status
Participants were evaluated clinically for cognitive impairment at each visit.63,64
We used the last visit clinical diagnosis to define the cognitive status of the participants
as normal cognition, impaired cognition (but not MCI; presence of medical
comorbidities), MCI, or dementia.98
Neuropathological assessment
Details of neuropathological assessment at UK-ADRC 16,71 and NACC99 have
been described previously. Aβ was considered present when neuritic or diffuse plaques9
were at least sparse. Braak NFT stages were dichotomized into an indicator for high
Braak NFT stage V-VI vs. I-IV. TDP-43 proteinopathy was considered present if TDP-43
inclusion bodies were detected in the hippocampus, whereas α-synuclein proteinopathy
was considered present when Lewy bodies were detected in the brain stem, neocortex, or
the medial temporal lobe.
Cerebrovascular pathology included measures of cerebral amyloid angiopathy,
categorized as moderate/severe vs. none/mild; atherosclerosis severity at Circle of Willis
(all vessels ≥50% vs. <50% occluded); any infarcts/lacunes (yes vs. no); and, brain
arteriolosclerosis (moderate/severe vs. none/mild). Cerebral atrophy was classified
moderate/severe vs. none/mild. Additionally, both right and left hippocampi were
evaluated for hippocampal sclerosis (HS) in UK-ADRC cases; the presence of HS on
either side was considered as HS. For NACC, HS was considered present if right and/or
left HS was reported, but not all ADRCs assess both sides of the hippocampal
formation.99
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Analyses and statistical methods
All analyses were first performed for UK-ADRC data, and then the same analyses
were applied to the NACC data to attempt to replicate the results. We used GBMTM
100,101

to estimate latent trajectories in the decade before death and compared the

trajectories and group membership characteristics to evaluate whether the trajectories
were similar despite differences in recruitment and population characteristics.
To fit the GBMTM, we first fit separate GBTM for each test; we fit three, four,
and five group models to determine the best-fitting number of trajectories. Four
trajectories were selected for each of the three tests based on the Bayesian Information
Criterion (BIC). A selection criterion was the mean maximum posterior probability in all
trajectory groups being > 0.7, meaning on average every participant assigned to a
trajectory has >70% probability of membership.85 Age at death, sex, and education were
included in the GBTM to account for their influence on group membership, but
neuropathology and clinical diagnoses were not included.
Once we determined the best fitting number of trajectories for each measure, we
fit a single GBMTM with four latent groups. Trajectory membership is probabilistic and
based on the participant’s performance on all three tests simultaneously. Each participant
has an estimated probability of membership in each trajectory group, with a total
probability equal to 1.0; maximum probability assignment was used to determine
membership for post-hoc analyses. Further, once optimal GBMTM models were selected,
we assessed trajectory face validity by examining the longitudinal mean scores of the
participants assigned to each trajectory group.
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Multinomial logistic regression was used to estimate the association of
demographic characteristics and neuropathology with trajectory membership, with No
Decline as the reference. Adjusted odds ratios (AOR) with 95% confidence intervals (CI)
were obtained from the model, which included age at death, sex, education, APOE ε4
(indicator for any ɛ4 alleles vs. none), and indicators for the presence of Braak NFT stage
V/VI, Aβ, TDP-43, atherosclerosis, arteriosclerosis, α-synuclein, and HS. While
analyzing NACC data, indicator variables for ADRC were included as a fixed effect to
account for center effects.
Because the multinomial logistic model requires the estimation of many
parameters relative to other logistic models,102 we could include only some variables of
interest. To consider the relative importance of all variables of interest (Table 3.1) in
explaining overall trajectory group membership; random forest (RF) and bagging
ensemble algorithm,103 which is a reliable variable selection method and produces
unbiased variable importance were then applied.104 As a sensitivity analysis, we repeated
the analyses on the subgroups of participants who began the follow-up interval with
normal cognition.
PROC TRAJ was used to estimate GBTM and GBMTM;100 PROC LOGISTIC
was used to fit the multinomial logistic regression (SAS:9.4®). RF was conducted using
the cforest function in the “party” R package.103 The reported results for multinomial and
RF analysis are based on multiple imputation of missing neuropathological data (Table
3.2). The imputation was conducted by chained random forest using imputation with
predictive mean matching with 5-iterations and 100 trees. The imputation was conducted
using the “missRanger” R package.105 The significance level was set at 0.05.
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Results
Participants’ characteristics
UK-ADRC included 365 autopsied participants (Figure 3.1a): mean (SD) age at
death was 87.0 (8.0) years; educational attainment was 15.6 (3.0) years; median annual
visit numbers was 9.9 (IQR: 5-14 visits); majority were female (n=228, 62.5%), and
White race (n=354, 97.0%). Among autopsied NACC participants (n=981): mean age at
death was 80.7 (9.6) years; education was 15.4 (3.1) years; median annual 5.0 visits
(IQR: 3-7 visits); majority were male (n=527, 53.7%); and White race (n=911, 92.9%). A
smaller proportion of UK-ADRC participants carried the APOE-ε4 allele (36.2% vs
45.8%) or had a dementia diagnosis at the time of death (56.2% vs 82.1%) versus NACC
(Table 3.1).
Cognitive trajectories
Participants in the UK-ADRC and NACC overall showed similar cognitive
trajectories (Figure 3.2): we labeled the trajectories as “No Decline” (mean test scores
remained normal during follow-up); “Mild Decline” (no decline in global cognition, slow
decline in memory and fluency); “Moderate Decline” (decline from normal to abnormal
global cognition, memory, and fluency); and, “Accelerated Decline” (decline from
abnormal to severe impairment in global cognition, memory, and fluency). Figure 3.2
and Figure 3.3 (participants who started follow-up with normal cognition) show the
observed means (dashed lines) and the estimated means (solid lines) with 95% CI for
each trajectory.
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Cognitive trajectories in the UK-ADRC
The No Decline group, comprising 27.9% of UK-ADRC participants (Figure
3.2), had better mean cognitive scores throughout follow-up than the other groups across
all tests. Mean MMSE scores remained relatively stable, while mean Logical Memory
and Animal Naming scores showed a slight decline but remained normal throughout
follow-up. The Mild Decline group (29.6%) declined marginally in the MMSE and
Animal Naming trajectories, but the group was distinct from No Decline due to
decreasing mean Logical Memory scores about 7-8 years before death. Moderate Decline
(25.8%) started with normal mean MMSE scores but rapidly declined 6 to 7 years before
death, while the Logical Memory trajectory started in the normal range and dropped to
abnormal. However, Animal Naming scores were relatively better preserved. Accelerated
Decline (16.7%) had abnormal scores 10 years before death. This group had low scores in
all three cognitive scores, but Logical Memory scores were most affected.
Among UK-ADRC participants who started follow-up with normal cognition
(n=228) (Figure 3.3), trajectory patterns were slightly different. MMSE trajectory for
Accelerated Decline started with >26 mean MMSE and declined rapidly about 8 years
before death. However, the mean Logical Memory and Animal Naming scores at baseline
were 10.5, and 16.1, respectively, and declined rapidly, about 6 years before death. The
Moderate Decline group also experienced decline in Logical Memory and Animal
Naming scores about 6 years before death.
Table 3.3 presents participant characteristics by trajectories. Compared to the
other groups, persons in the Accelerated Decline group on average died earlier, majority
were female, diagnosed with dementia at the last visit (98.4%), and had higher
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proportions of APOE ε4 allele (55.7%), Braak NFT stage V/VI (90.2%), TDP-43
proteinopathy (60.9%), HS (45.9%), moderate/severe Cerebral amyloid angiopathy
(42.6%), and moderate/severe cerebral atrophy (67.2%). The Mild Decline and No
Decline groups comparatively had a lower burden of APOE ε4 allele, proteinopathies,
cerebral atrophy, and HS than the Moderate and Accelerated groups. Among the
participants who began follow-up with normal cognition (n=228), those assigned to the
Accelerated Decline and Moderate Decline groups were older than the No Decline and
Mild Decline groups, and the burden of proteinopathies was higher (Table 3.4).
Multinomial logistic regression estimated associations between participant
characteristics and trajectory membership (Table 3.7). With a 5-year increase in age at
death, participants were less likely to be in the Accelerated Decline group (aOR= 0.68;
95% CI, 0.51, 0.92). Braak NFT stage V/VI was strongly associated with higher odds of
belonging to the Accelerated Decline (AOR =43.95; 95% CI, 12.00,163.98), Moderate
Decline (AOR = 17.69; 95% CI, 7.69-44.10), and Mild Decline (AOR = 3.58; 95% CI,
1.66, 7.70) group membership compared to No Decline. Presence of TDP-43
proteinopathy had higher odds of being in the Accelerated Decline group (AOR = 3.52;
95% CI, 1.04, 12.87). While HS was significantly associated with group membership,
this association was not significant in complete case analyses (Table 3.8). There was no
significant association of α-synuclein, atherosclerosis, or APOE ε4 with group
membership.
Cognitive trajectories in NACC
NACC included 981 autopsied participants (Figure 3.1b): On average,
individuals in all NACC trajectory groups died younger (~6 years) than UK-ADRC
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participants (Table 3.5). Estimated cognitive trajectories in NACC were similar in shape
to those in UK-ADRC (Figure 3.2b): No Decline (16.0%), Mild Decline (31.3%),
Moderate Decline (38.3%), and Accelerated Decline (14.4%) groups, but the distribution
of membership differed. In addition, estimated mean Logical Memory and Animal
Naming scores were lower at the beginning of follow-up compared to the UK-ADRC
participants. Participant characteristics of the NACC trajectory groups are presented in
Table 3.5 and Table 3.6 (participants starting as normal).
Based on multinomial logistic regression (Table 3.7), a 5-year increase in age at
death was associated with lower odds of Accelerated Decline (AOR = 0.57; 95% CI,
0.48, 0.67) and Moderate Decline (AOR = 0.69; 95% CI, 0.60, 0.79) membership versus
No Decline. Braak NFT stage V/VI (AOR =26.18; 95% CI, 12.07, 56.82) and TDP-43
pathology (AOR = 4.32; 95% CI, 2.07, 8.99) were associated with Accelerated Decline.
The Accelerated Decline (AOR =2.54; 95% CI, 1.37, 4.68), Moderate Decline (AOR =
3.36; 95% CI, 1.75, 6.44), and Mild Decline (AOR = 2.23; 95% CI, 1.19, 4.18) groups
were associated with higher odds of having α-synuclein compared to the No Decline.
Moderate/severe arteriosclerosis was associated with higher odds of membership in the
Accelerated Decline (AOR = 3.05; 95% CI, 1.69, 5.49), Moderate Decline (AOR =1.92;
95% CI, 1.18, 3.12), and Mild Decline (AOR = 1.75; 95% CI, 1.11, 2.75). Complete case
analyses are presented in Table 3.8.
Distribution of Multiple pathologies by trajectory groups
Figure 3.4 shows the frequencies of AD neuropathologic change (ADNC) and
comorbid brain pathologies by trajectory groups. Over 80% of UK-ADRC cohort and
>86% of NACC cohort brains had ADNC pathology with at least one comorbid
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pathology. The Moderate Decline and Accelerated Decline groups had higher frequencies
of quadruple misfolded proteins (QMP) i.e. presence of all four misfolded proteins,23 as
well as the presence of TDP-43 with cerebrovascular pathologies. The presence of ≥ 2
proteinopathies was also largely accompanied by moderate/severe cerebrovascular
pathologies (Figure 3.4).
In the RF analysis, all 16 predictors (Table 3.1) were evaluated to assess their
importance in classifying participants into trajectory groups (Figure 3.6). For UK-ADRC
participants, the five most important variables were Braak NFT stage, cerebral atrophy,
HS, brain weight, and age at death. Similarly, for NACC cases, Braak NFT stage, age at
death, cerebral atrophy, brain weight, and α-synuclein were most important.
Discussion
We estimated cognitive trajectories among ADRC volunteers in their last decade
of life based on longitudinal patterns of three cognitive test scores, considered
simultaneously. GBMTM models identified four trajectories (we labeled as: No, Mild,
Moderate, and Accelerated Decline) in both the UK-ADRC and NACC datasets.
Although the NACC participants died younger and had, generally, worse cognitive status
compared to the UK-ADRC participants, the trajectories during end of life, and the
underlying pathologies, were quite similar.
The GBMTM approach allowed us to account for how longitudinal performance
on each test was related to longitudinal performance on the other two tests. Importantly,
the results have good face validity, which was assessed by mean scores in each trajectory
groups (e.g., participants assigned to the No Decline group should have observed scores
indicating normal cognition).
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One of the strengths of the GBMTM method is the ability to characterize patterns
of variation in longitudinal outcomes. In both cohorts, although the Moderate and the
Accelerated Decline groups had a pronounced decline in the test scores before death, the
trajectory patterns were dissimilar. Mean test scores in the Accelerated Decline group
were lower at the start and showed a constant decline, and almost 100% of participants
had dementia diagnoses. Accelerated Decline was associated with proportionally greater
burden of proteinopathies and cerebrovascular pathologies than the other trajectory
groups. The Moderate Decline trajectory scores rapidly decreased starting about 8 years
before death, and >90% carried a dementia diagnosis. However, looking at the individual
tests, the Logical Memory and Animal Naming scores were low a decade before death,
whereas the Mild Decline group participants showed decline only in the last 4-5 years
before death. These findings suggest that GBMTM models may be useful in recognizing
the subpopulations of older adults that show varied patterns of cognitive performance and
potentially disease burden.
Consistent with previous studies, neocortical tau proteinopathy (the pathology
found in Braak NFT stages V/VI) was strongly associated with cognitive decline.16
Results from both the multinomial logistic and RF analyses emphasized the importance
of Braak NFT stages in trajectory membership probabilities. However, point estimates
from the multinomial model should be interpreted with caution due to the wide
confidence intervals, which arose primarily due to sparse cells in the Braak NFT stages
I/II/III/IV in the Accelerated and the Moderate Decline groups. Even so, we consider the
association very strong.
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Also consistent with previous studies was the lack of a strong association between
amyloid-β (in the absence of high Braak NFT stages) and cognitive trajectories.16,106
Amyloid plaques were present in all trajectory groups and did not predict group
membership in the multinomial analysis, and the RF analysis also showed amyloid was
not important for group membership. Although the APOE ε4 carrier proportions were
>40% in the Moderate and Accelerated decline groups, after controlling for the other
proteinopathies there was no association with trajectory groups, except with the Moderate
Decline group in the NACC cohort. The association between APOE ε4 and late-life
cognitive decline appears to be mediated primarily by the relationship between APOE
and ADNC, and once ADNC affects cognition, the association between APOE and
cognition is diminished.107
TDP-43 proteinopathy was prevalent in Accelerated and Moderate Decline groups
and was strongly associated with group membership. TDP-43 proteinopathy has a strong
association with cognitive impairment,23,25,26 and is associated independently with
cognitive decline in the presence or absence of comorbid ADNC.25,81 Presence of αsynuclein proteinopathy was strongly associated with group membership among the
NACC participants but not among the UK-ADRC participants, perhaps due to age
differences in the two cohorts, given that participants with α-synuclein proteinopathy die
at a relatively younger age.50 Moderate/severe atherosclerosis and arteriosclerosis were
also strongly associated with the Accelerated Decline group. Furthermore,
moderate/severe cerebral atrophy was proportionally higher in Accelerated and Moderate
Decline and was one of the five of the most important variables in the RF analysis. The
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confluence of proteinopathies, age at death, cerebrovascular pathologies, cerebral
atrophy, HS, and brain weight appeared to play roles in the slopes of the trajectories.
This study has several strengths. First was the availability of longitudinal followup with both clinical and neuropathological data. Second, we were generally able to
replicate UK-ADRC results with NACC data collected from different ADRCs. Third,
careful assessment of missing data and performing multiple imputation increased the
validity of our findings. Additionally, we performed a sensitivity analysis in participants
who started follow-up with clinically normal cognition, allowing a basis for clinical
inference with respect to a presumed normal baseline. Although there were differences in
the cohorts in terms of age at death, proportions of APOE ε4 allele, TDP-43, α-synuclein,
cerebrovascular diseases, and hippocampal sclerosis, multiple comorbidities were
prevalent in Moderate and Accelerated Decline groups from both cohorts.
The study has some limitations, however. There is possible misclassification of
the trajectory group membership due to missing data and the fact that group membership
is probabilistic. Available genetic data were limited to APOE genotype. In addition, our
results have limited generalizability, as our data were restricted to primarily white, welleducated, and autopsied participants. Future studies are needed that focus on living
populations with more demographically diverse research volunteers. Finally, residual
center effects may persist despite adjustment for the centers, though prior research has
shown good to an excellent agreement in neuropathologic ratings across various
ADRCs.9
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Conclusion
In conclusion, this study provides evidence that older adults follow distinct
trajectories of cognitive performance during end of life. The relationship between
trajectory groups and cognitive performance correlated with both the number of
proteinopathies and the burden of cerebrovascular pathology in the brain. Despite the
younger age at death of the NACC participants compared to the UK-ADRC participants,
strikingly similar neuropathologic profiles featuring multiple pathologies were associated
with trajectories. Thus, the high burden of complex neuropathologies is not exclusively a
phenomenon of extreme old age, and prevention and treatment strategies focused on a
single disease may fail to decrease the dementia burden in the population.
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Figure 3.1a. Participant Inclusion Flow Diagram

Total Brain Bank Autopsies (UK-ADRC)
N=884

Exclusions
•
•
•
•
•
•

No TDP-43 neuropathology data (n=449)
Braak stage 0 (n=34)
FTLD (n=13)
Rare Dementia Syndrome (n=9)
Down syndrome (n=4)
Missing test scores (n=10)

Participants included
n= 365

UK-ADRC, University of Kentucky Alzheimer’s Disease Research Center; TDP-43,
transactive response DNA binding protein 43 kDa; FTLD, Frontotemporal lobar
degeneration.
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Figure 3.1b. Participant Inclusion Flow Diagram

Total Brain Bank Autopsies (NACC)
N=5,982

Exclusions
•
•
•
•
•
•
•
•
•

UK-ADRC data (n=356)
No TDP-43 neuropathology data (n=4,017)
Enrollment age < 55 (n=93)
No Lewy body data (n=2)
Braak stage 0 (n=126)
No Aβ data (n=51)
Down syndrome (n=2)
Rare Dementia Syndrome (n=290)
Missing test scores (n=66)

Participants included
n= 981
NACC, National Alzheimer’s Coordinating Center; TDP-43, transactive response
DNA binding protein 43 kDa; FTLD, Frontotemporal lobar degeneration.
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Table 3.1. Participant Characteristics by Cohort
Variable
N (%)
Number of visits mean ± SD
Age at death, y
Female sex
White race
Education, y , mean ± SD
APOE ε4 allele
Baseline Clinical Diagnosis
Normal
Impaired
MCI
Demented
Last Clinical Diagnosis
Normal
Impaired
MCI
Demented
Whole brain weight (g), mean ± SD
Braak NFT stage
Braak I to IV
Braak V to VI
Cerebral atrophy
None/Mild
Moderate/severe
Aβ plaques
α-synuclein
TDP-43 inclusion bodies
Hippocampal sclerosis
Cerebral amyloid angiopathy
None/Mild
Moderate/severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded
Arteriosclerosis
None/Mild
Moderate/Severe
Infarcts
None
Present

UK-ADRC
n=365
9.9 (5.7)
87.0 (8.0)
228 (62.5)
354 (97.0)
15.6 (3.0)
132 (36.2)

NACC
n=981
4.9 (2.7)
80.7 (9.6)
454 (46.3)
911 (92.9)
15.4 (3.1)
449 (45.8)

228 (62.5)
7 (1.9)
24 (6.6)
92 (25.2)

163 (16.6)
26 (2.6)
190 (19.4)
602 (61.4)

104 (28.5)
10 (2.7)
45 (12.3)
205 (56.2)
1146.7 (157.2)

85 (8.6)
18 (1.8)
73 (7.4)
805 (82.1)
1153.2 (169.7)

190 (52.0)
175 (48.0)

336 (34.2)
645 (65.8)

253 (67.5)
122 (32.5)
317 (86.8)
112 (30.7)
137 (37.5)
92 (24.5)

557 (49.8)
488 (43.2)
910 (92.8)
380 (38.7)
263 (26.8)
144 (14.8)

274 (63.3)
89 (24.7)

488 (49.8)
424 (43.2)

143 (39.2)
218 (59.7)

613 (62.5)
362 (36.9)

231 (63.3)
90 (24.7)

437 (44.6)
535 (54.4)

201 (55.1)
164 (44.9)

656 (66.8)
322 (32.8)

UK-ADRC, University of Kentucky Alzheimer’s Disease Research Center; NACC, National
Alzheimer’s Coordinating Center; APOE, Apolipoprotein E; Aβ, Amyloid-β;
TDP-43, transactive response DNA binding protein 43 kDa; NFT, Neurofibrillary tangles.
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Table 3.2: Frequency of Missing Data in all Participants
Variable
Education
APOE ε4 allele (≥1 allele)
Baseline Clinical Diagnosis
Last Clinical Diagnosis (last visit)
Hippocampal sclerosis
Atherosclerosis
Arteriosclerosis
Infarcts/lacunes
Cerebral atrophy
Cerebral amyloid angiopathy
Whole brain weight

UK-ADRC
(n=365)
5 (1.4)
16 (4.4)
14 (3.8)
1 (0.3)
4 (1.1)
4 (1.1)
44 (12.1)
4 (1.1)
2 (0.5)
-

NACC
(n=981)
9 (0.9)
103 (10.5)
5 (0.5)
6 (0.6)
9 (0.9)
11 (1.1)
(7.0)
3 (0.3)
6 (0.6)

UK-ADRC, University of Kentucky Alzheimer’s Disease Research Center;
NACC, National Alzheimer’s Coordinating Center.
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Figure 3.2a: Group-based Multi-trajectory Modeling was used to Identify End-of-life
Latent Cognitive Trajectories in Autopsied Research Volunteers (UK-ADRC).
Within Each Cohort, there is a 1:1 Correspondence of Group Membership in the Plots
UK-ADRC
Mini-Mental State Examination

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
29.2 (29.2-29.2)
28.7 (28.6-28.8)
28.3 (28.0-28.5)
27.8 (27.2-28.3)

Mild
Moderate
28.6 (28.4-28.9)
27.7 (26.7-28.7)
27.4 (27.0-27.7)
24.6 (23.8-25.5)
26.2 (25.6-26.8)
19.9 (19.2-20.6)
24.9 (23.9-26.0)
10.6 (8.5-12.7)
Logical Memory (Immediate recall)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
17.3 (16.7-17.9)
16.5 (16.2-16.8)
16.0 (15.6-16.3)
15.4 (14.8-16.0)

Mild
Moderate
15.7 (15.2-16.3)
12.0 (11.0-12.9)
13.0 (12.7-13.3)
7.3 (6.6-8.0)
10.9 (10.5-11.4)
3.7 (2.8-4.6)
8.9 (8.2-9.6)
1.0 (0.7-1.4)
Animal Naming Test

Accelerated
4.4 (1.9-6.9)
1.3 (0.8-1.7)
0.3 (0.0-0.8)
0.0 (0.0-0.6)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
23.0 (22.4-23.7)
20.9 (20.5-21.2)
19.3 (18.8-19.7)
17.6 (17.0-18.3)

Mild
17.6 (16.7-18.6)
15.6 (15.0-16.2)
13.5 (13.0-14.0)
11.6 (10.6-12.7)

Accelerated
12.9 (10.8-15.1)
6.8 (5.3-8.3)
2.9 (1.3-4.5)
0.7 (0.3-1.1)

Moderate
16.9 (16.0-17.8)
13.1 (16.0-13.6)
10.3 (16.0-11.0)
7.5 (16.0-8.8)

Accelerated
18.4 (17.3-19.5)
12.1 (11.4-12.8)
7.4 (6.4-8.5)
3.3 (1.8-4.8)

Number of trajectory groups are based on most parsimonious multi-trajectory models.
Trajectory groups: No Decline (purple), Mild Decline (green), Moderate decline (blue) and
Accelerated Decline (red).Shaded areas are 95% CI. The tables present test scores 10, 6, 3,
and in <1 year before death.
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Figure 3.2b: Group-based Multi-trajectory Modeling was used to Identify End-of-life
Latent Cognitive Trajectories in Autopsied Research Volunteers (NACC)
NACC

Mini-Mental State Examination

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
Mild
Moderate
29.0 (28.9-29.2) 28.2 (27.2-29.1) 24.3 (22.7-25.9)
28.8 (28.7-28.9) 27.0 (26.5-29.3) 23.7 (23.2-24.2)
28.5 (28.3-28.7) 26.0 (25.5-28.7) 19.7 (19.4-20.1)
27.8 (27.3-28.3) 21.2 (20.5-28.1) 12.7 (12.1-13.2)
Logical Memory (Immediate recall)

Accelerated
22.9 (21.8-24.1)
14.9 (14.4-15.5)
8.9 (8.2-9.6)
3.4 (2.1-4.6)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
17.3 (16.6-18.0)
16.2 (15.8-16.5)
15.3 (15.1-15.6)
14.5 (14.1-14.9)

Mild
Moderate
11.1 (10.1-12.1) 7.4 (5.9-8.9)
10.5 (10.2-10.9) 5.1 (4.5-5.7)
8.3 (8.0-8.7)
3.0 (2.6-3.4)
4.8 (4.1-5.4)
1.1 (1.0-1.3)
Animal Naming Test

Accelerated
4.4 (3.0-5.8)
1.7 (1.4-2.1)
0.6 (0.5-0.7)
0.1 (0.0-0.5)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
24.5 (23.7-25.3)
22.0 (21.5-22.4)
20.1 (19.7-20.5)
18.2 (17.6-18.8)

Mild
15.0 (13.7-16.3)
15.5 (15.0-15.9)
13.6 (13.2-14.0)
9.8 (9.1-10.5)

Accelerated
11.3 (9.9-12.7)
6.3 (5.4-7.1)
3.2 (2.4-3.9)
1.1 (1.1-1.2)

Moderate
14.0 (12.5-15.5)
12.5 (12.0-13.1)
9.5 (9.0-10.0)
5.1 (4.2-5.9)

Number of trajectory groups are based on most parsimonious multi-trajectory models.
Trajectory groups: No Decline (purple), Mild Decline (green), Moderate decline (blue) and
Accelerated Decline (red). Shaded areas are 95% CI. The tables present test scores 10, 6, 3,
and in <1 year before death.
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Figure 3.3a: Group-based Multi-trajectory Modeling was used to Identify Endof-life Latent Cognitive Trajectories in Autopsied Research Volunteers Who
Started as Cognitively Normal.
UK-ADRC
Mini-Mental State Examination

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
29.1 (29.1-29.2)
28.8 (28.7-29.0)
28.6 (28.4-28.8)
28.3 (27.9-28.7)

Mild
29.4 (29.3-29.5)
28.4 (28.1-28.8)
27.4 (26.8-28.2)
26.5 (25.3-27.8)

Moderate
28.8 (28.5-29.0)
27.2 (26.9-27.6)
25.7 (25.1-26.2)
23.9 (23.1-24.8)

Accelerated
26.6 (25.4-28.0)
23.0 (22.2-23.8)
15.5 (14.8-16.3)
4.3 (1.6-6.9)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
18.0 (17.3-18.6)
17.2 (16.8-17.6)
16.7 (16.2-17.2)
16.1 (15.4-16.8)

Mild
13.7 (12.7-14.7)
13.1 (12.6-13.8)
12.8 (12.1-13.4)
12.4 (11.4-13.4)

Moderate
14.8 (14.1-15.5)
12.5 (12.1-13.0)
9.5 (9.1-10.1)
4.7 (4.0-7.3)

Accelerated
10.5 (9.5-11.5)
5.8 (5.0-6.5)
2.6 (1.6-3.7)
0.7 (0.7-0.7)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
21.0 (20.3-21.7)
19.6 (19.2-20.1)
18.6 (18.0-19.1)
17.5 (16.7-18.3)

Mild
28.2 (26.7-29.7)
22.5 (21.8-23.3)
19.5 (18.6-20.4)
17.5 (16.3-18.7)

Moderate
17.7 (17.1-18.4)
14.7 (14.4-15.1)
12.5 (11.9-13.0)
10.2 (9.3-11.1)

Accelerated
16.1 (15.0-17.1)
11.0 (10.4-11.7)
7.3 (6.0-8.7)
3.9 (1.8-6.1)

Logical Memory (Immediate recall)

Animal Naming test

Number of trajectory groups are based on most parsimonious multi-trajectory models.
Trajectory groups: No Decline (purple), Mild Decline (green), Moderate decline (blue)
and Accelerated Decline (red). Shaded areas are 95% CI. The tables present test scores
10, 6, 3, and in < 1 year before death. UK-ADRC, University of Kentucky-Alzheimer’s
Disease Center.
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Figure 3.3b: Group-based Multi-trajectory Modeling was used to Identify End-oflife Latent Cognitive Trajectories in Autopsied Research Volunteers Who Started
as Cognitively Normal
NACC

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
29.7 (29.4-30.0)
29.7 (29.5-29.8)
29.6 (29.5-297)
29.6 (29.5-29.7)

Mild
29.2 (28.8-29.5)
29.1 (29.0-29.3)
28.9 (28.7-29.1)
28.4 (27.8-29.0)

Moderate
28.4 (27.2-29.5)
28.6 (28.2-28.9)
27.3 (27.4-28.3)
26.0 (25.2-26.9)

Accelerated
29.0 (28.3-29.6)
24.8 (24.0- 25.5)
21.0 (20.2-21.8)
17.2 (15.9-18.4)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
17.8 (16.9-18.6)
17.8 (16.9-18.6)
17.8 (16.9-18.6)
17.8 (16.9-18.6)

Mild
16.0 (15.6-16.4)
16.0 (15.6-16.4)
16.0 (15.6-16.4)
16.0 (15.6-16.4)

Moderate
11.0 (9.3-12.8)
11.9 (11.3-12.5)
11.1 (10.6-11.6)
8.9 (8.0-9.9)

Accelerated
11.5 (9.8-13.1)
8.9 (7.9-9.8)
6.9 (5.6-83)
5.1 (2.7-7.5)

Years
-10 yrs
-6 yrs
-3 yrs
< -1 yrs

No
33.4 (31.6-35.1)
30.9 (30.0-31.8)
29.0 (28.0-30.0)
27.2 (25.6-28.8)

Mild
22.3 (21.2-23.3)
21.1 (20.5-21.7)
20.2 (19.7-20.7)
19.3 (18.5-20.1)

Moderate
17.4 (16.1-18.7)
15.6 (15.0-16.3)
14.3 (13.8-14.8)
13.0 (12.1-13.9)

Accelerated
16.5 (14.5-18.5)
13.6 (12.5-14.7)
11.5 (10.1-12.8)
9.3 (6.8-11.8)

Number of trajectory groups are based on most parsimonious multi-trajectory models.
Trajectory groups: No Decline (purple), Mild Decline (green), Moderate decline (blue)
and Accelerated Decline (red).Shaded areas are 95% CI. The tables present test scores
10, 6, 3, and in < 1 year before death. NACC, National Alzheimer’s Coordinating
Center.
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Table 3.3: UK-ADRC Participant Characteristics by Trajectory Group (N=365)
Variable
N (%)
Age at death, y mean (SD)
Female sex
Race (White)
Education, y mean (SD)
APOE ε4 allele (≥1 allele)
Last Clinical Diagnosis
Normal
Impaired/Other
MCI
Dementia
Whole brain weight (g)
mean (SD)
Aβ Plaques (present)
α-synuclein (present)
TDP-43 inclusion bodies
Braak NFT stage
I to IV
V to VI
Cerebral atrophy
None/Mild
Moderate/Severe
Hippocampal Sclerosis
Cerebral amyloid angiopathy
None/Mild
Moderate/severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded

No
Decline
102 (27.9)

Mild
Decline
108 (29.6)

Moderate
Decline
94 (25.8)

Accelerated
Decline
61 (16.7)

72 (70.6)
5 (4.9)
15 (14.7)
10 (9.8)
1212.1
(134.2)
81 (79.4)
24 (23.5)
20 (19.6)

30 (27.8)
4 (3.7)
27 (25.0)
47 (43.5)
1164.9
(141.9)
92 (85.2)
27 (25.0)
35 (31.0)

2 (2.1)
1 (1.0)
3 (3.2)
88 (93.6)
1113.7
(174.3)
85 (90.4)
32 (34.0)
48 (50.0)

0
0
0
60 (98.4)
1056.1
(136.6)
59 (96.7)
29 (47.5)
39 (60.9)

87 (85.3)
15 (14.7)

70 (64.8)
38 (36.2)

27 (28.7)
67 (71.3)

6 (9.8)
55 (90.2)

93 (91.2)
8 (7.8)
9 (8.8)

87 (80.6)
20 (18.5)
16 (14.8)

44 (46.8)
49 (52.1)
37 (39.4)

10 (31.2)
41 (67.2)
28 (45.9)

87 (85.3)
15 (14.7)

83 (76.8)
25 (23.2)

70 (74.5)
23 (24.5)

34 (55.7)
26 (42.6)

48 (47.1)
54 (52.9)

37 (34.3)
71 (65.7)

37 (39.4)
56 (59.6)

21 (34.4)
37 (60.7)

87.1 (6.1)
60 (58.8)
102 (100.0)
16.7 (2.6)
28 (27.5)

89.0 (6.7)
64 (59.3)
101 (93.5)
15.7 (2.8)
32 (29.6)

87.6 (8.8)
60 (63.8)
91 (96.8)
15.1 (3.1)
38 (40.4)

82.4 (9.6)
44 (72.1)
60 (98.4)
14.4 (3.4)
34 (55.7)

Arteriosclerosis
None/Mild
64 (62.8)
70 (64.8)
64 (68.1)
33 (54.1)
Moderate/Severe
26 (25.5)
28 (25.9)
23 (24.5)
13 (21.3)
Infarcts/Lacunes
Yes
58 (56.9)
53 (49.1)
53 (56.4)
37 (60.7)
No
44 (43.1)
55 (50.9)
41 (43.6)
24 (39.3)
Mean (SD) or proportion as shown. SD, standard deviation; Abbreviations: UK-ADRC,
University of Kentucky-Alzheimer’s Disease Research Center; .APOE, Apolipoprotein;
Aβ, Amyloid-β; TDP-43, transactive response DNA binding protein 43 kDa; NFT,
Neurofibrillary tangles; HS, Hippocampal Sclerosis.
Missing data are reported in Table 3.2.
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Table 3.4: UK-ADRC Participant Characteristics by Trajectory Group Among
Participants Who Started as Cognitively Normal (n=228)
Variable
N (%)
Age at death, y mean (SD)
Female sex
Race (White)
Education, y mean (SD)
APOE ≥ 1ε4 allele
Last Clinical Diagnosis
Normal
Impaired/Other
MCI
Dementia
Whole brain weight (g)
Mean (SD)
Aβ plaques (present)
α-synuclein (present)
TDP-43 inclusion bodies
Braak NFT stage
I to IV
V to VI
Cerebral atrophy
None/Mild
Moderate/Severe
HS (present)
Cerebral amyloid angiopathy
None/Mild
Moderate/Severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded
Arteriosclerosis
None/Mild
Moderate/Severe
Infarcts/Lacunes
No
Yes

No
Decline
78 (34.2)
87.0 (6.0)
50 (64.1)
78 (100.0)
16.3 (2.5)
16 (20.5)

Mild
Decline
31 (13.6)
87.5 (6.9)
15 (48.4)
30 (96.8)
17.3 (3.6)
12 (38.7)

Moderate
Decline
85 (37.3)
91.0 (5.6)
54 (63.5)
82 (96.5)
15.2 (2.2)
30 (35.3)

Accelerated
Decline
34 (14.9)
90.8 (6.8)
30 (88.2)
34 (100.0)
16.2 (2.3)
15 (44.1)

66 (84.6)
2 (2.6)
7 (8.9)
3 (3.9)
1201.2
(127.2)
61 (78.2)
16 (20.5)
15 (19.2)

17 (48.2)
1 (3.2)
8 (25.0)
7 (22.6)
1223.5
(157.2)
25 (80.7)
5 (16.1)
7 (22.6)

22 (27.1)
3 (3.5)
19 (22.3)
40 (47.1)
1145.5
(128.5)
75 (88.2)
16 (18.8)
29 (34.1)

0
0
1 (2.9)
33 (97.1)
1071.9
(106.2)
30 (88.2)
14 (41.2)
20 (58.8)

72 (92.3)
6 (7.7)

20 (64.5)
11 (35.5)

52 (61.2)
33 (38.8)

8 (22.5)
26 (76.5)

75 (96.2)
2 (2.6)
4 (5.2)

26 (83.9)
5 (16.1)
6 (19.4)

68 (80.0)
16 (18.8)
15 (17.7)

10 (29.4)
24 (70.6)
19 (55.9)

68 (88.3)
9 (11.5)

23 (74.2)
8 (27.1)

60 (72.9)
23 (27.1)

26 (70.6)
10 (29.4)

33 (42.3)
45 (57.7)

16 (51.6)
15 (48.4)

29 (34.1)
56 (65.9)

9 (26.5)
25 (75.5)

53 (68.0)
15 (19.2)

17 (54.8)
11 (24.7)

54 (63.5)
21 (24.7)

21 (61.8)
13 (38.2)

47 (60.3)
31 (39.7)

14 (45.2)
17 (54.8)

36 (42.4)
49 (57.6)

17 (50.0)
17 (50.0)

Mean (SD) or proportion as shown. SD, standard deviation; Abbreviations: UK-ADRC,
University of Kentucky Alzheimer’s Disease Research Center; .APOE Apolipoprotein E;
Aβ, Amyloid-β; TDP-43, transactive response DNA binding protein 43 kDa; NFT,
Neurofibrillary tangles; HS, Hippocampal Sclerosis.
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Table 3.5: NACC Participant Characteristics by Trajectory Group (N=981)
No
Decline
157(16.0)
85.1 (8.3)
69 (44.0)
147 (93.6)
16.5 (2.9)
41 (26.1)

Mild
Decline
307(31.3)
82.2 (9.5)
134 (43.7)
288 (93.8)
15.4 (3.1)
129 (42.0)

Moderate
Decline
376(38.3)
79.1 (9.1)
174 (46.3)
353 (93.9)
15.1 (3.1)
215 (57.2)

Accelerated
Decline
141(14.4)
76.9 (10.2)
77 (54.6)
123 (87.2)
15.3 (3.3)
64 (45.4)

74 (47.1)
13 (8.3)
42 (26.8)
28 (17.8)

11 (3.6)
4 (1.3)
31 (10.1)
261 (85.0)

0
1 (0.3)
0
375 (99.7)

0
0
0
141 (100.0)

1226.4 (137.8)

1193.6 (164.5)

1136.3 (148.6)

1029.2 (190.7)

Aβ Plaques

129 (82.2)

278 (90.6)

367 (97.6)

136 (96.5)

α-synuclein

31 (19.8)

124 (40.4)

157 (41.8)

68 (48.2)

TDP-43 inclusion bodies
Braak NFT stage
I to IV
V to VI
Cerebral atrophy
None/Mild
Moderate/Severe
Hippocampal Sclerosis
Cerebral amyloid angiopathy
None/Mild
Moderate/Severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded
Arteriosclerosis
None/Mild
Moderate/Severe
Infarcts/Lacunes
No
Yes

20 (12.7)

70 (22.8)

121 (32.2)

52 (36.9)

124 (79.0)
33 (21.0)

137 (44.6)
170 (55.4)

58 (15.4)
318 (84.6)

17 (12.1)
124 (87.9)

109 (69.4)
28 (19.1)
11 (7.0)

188 (61.2)
99 (32.3)
32 (10.4)

168 (44.7)
189 (50.3)
73 (19.4)

23 (16.3)
106 (75.2)
28 (19.9)

126 (82.9)
25 (16.5)

216 (70.8)
88 (28.9)

208 (54.5)
173 (45.3)

72 (50.7)
70 (49.3)

95 (60.5)
62 (39.5)

200 (65.2)
105 (34.2)

241 (64.1)
132 (35.1)

77 (54.6)
63 (44.7)

91 (58.0)
65 (41.4)

137 (44.6)
168 (54.7)

163 (42.7)
214 (56.0)

48 (34.0)
92 (65.3)

99 (63.1)
57 (36.9)

200 (65.2)
106 (34.5)

251 (66.8)
123 (32.7)

106 (75.2)
35 (24.8)

Variable
Age at death, y, mean (SD)
Female sex
Race (White)
Education, y, mean (SD)
APOE ε4 allele (≥1 allele)
Last Clinical Diagnosis
Normal
Impaired/Other
MCI
Dementia
Whole brain weight (g)
Mean (SD)

Mean (SD) or proportion as shown. SD, standard deviation; Abbreviations: NACC,
National Alzheimer’s Coordinating Center. APOE, Apolipoprotein; Aβ, Amyloid-β;
TDP, transactive response DNA binding protein 43 kDa; NFT, Neurofibrillary tangles.
Missing data are reported in Table 3.2.
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Table 3.6: NACC Participant Characteristics by Trajectory Group Among Participants
Who Started as Cognitively Normal (n=163)
Variable
Age at death, y mean (SD)
Female sex
Race (White)
Education, y mean (SD)
APOE ε4 allele (≥1 allele)
Last Clinical Diagnosis
Normal
Impaired/Other
MCI
Dementia
Whole brain weight (g)
mean (SD)
Aβ plaques
α-synuclein
TDP-43 inclusion bodies
Braak NFT stage
I to IV
V to VI
Cerebral atrophy
None/Mild
Moderate/Severe
HS
Cerebral amyloid angiopathy
None
Moderate/Severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded
Arteriosclerosis
None/Mild
Moderate/Severe
Infarcts /Lacunes
No
Yes

No
Decline
15 (9.2%)
84.8 (6.2)
12 (80.0)
15 (100.0)
16.7 (3.0)
4 (26.7)

Mild
Decline
69 (42.3%)
86.4 (8.3)
32 (46.4)
67 (97.1)
16.4 (3.1)
16 (23.2)

Moderate
Decline
67 (41.1%)
88.4 (6.6)
43 (64.2)
57 (85.1)
15.1 (2.8)
19 (28.4)

Accelerated
Decline
12 (7.4%)
89.8 (11.8)
11 (91.7)
11 (91.7)
15.5 (3.0)
7 (58.3)

9 (60.0)
2 (13.3)
3 (20.0)
1 (6.7)
1215.9
(108.7)

47 (68.1)
2 (2.9)
13 (18.8)
7 (10.1)
1228.7
(148.8)

19 (28.4)
7 (10.4)
16 (23.9)
25 (37.3)
1159.0
(191.6)

0
0
1 (8.3)
11 (91.7)
1085.6
(83.0)

12 (80.0)
2 (13.3)
2 (13.3)

54 (78.3)
12 (17.4)
7 (10.1)

60 (89.6)
12 (17.9)
8 (11.9)

12 (100.0)
1 (8.3)
3 (25.0)

11 (73.3)
4 (26.7)

59 (85.5)
10 (14.5)

46 (68.7)
21 (31.3)

4 (33.3)
8 (66.7)

11 (73.3)
1 (6.7)
0 (0.0)

49 (71.0)
13 (18.8)
5 (7.3)

49 (73.1)
15 (22.4)
6 (8.9)

3 (25.0)
9 (75.0)
0 (0.0)

14 (93.3)
1 (6.7)

60 (87.0)
9 (13.0)

49 (73.1)
18 (26.9)

8 (66.7)
4 (33.3)

9 (60.0)
6 (40.0)

40 (58.0)
29 (42.0)

37 (55.2)
30 (44.8)

6 (50.0)
6 (50.0)

9 (60.0)
6 (40.0)

41 (59.4)
28 (40.6)

30 (44.8)
37 (55.2)

5 (41.7)
6 (50.0)

14 (93.3)
1 (6.7)

62 (89.9)
7 (10.6)

52 (77.6)
15 (22.4)

11 (91.7)
1 (8.3)

Mean (SD) or proportion as shown. SD, standard deviation; Abbreviations: NACC,
National Alzheimer’s Coordinating Center. APOE, Apolipoprotein E; Aβ, Amyloid-β;
TDP-43, transactive response DNA binding protein 43 kDa; NFT, Neurofibrillary
tangles.
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Table 3.7: Multinomial Logistic Regression was used to Estimate Adjusted Odds Ratios
(AOR) of Membership in a Group with Cognitive Decline vs. No Decline Within
Cohorts. Results are Based on Models Fully Adjusted for all Variables Listed
Variable
UK-ADRC ( n=365)
Age at death (5-yr increase)
Sex

Accelerated vs No

Education
APOE ε4 allele ≥1 vs 0
Braak NFT stage
(V to VI) vs (I to IV)
TDP-43 Yes vs No
Aβ Yes vs No
α-Synuclein Yes vs No
Atherosclerosis
>50% vs <50% Occluded
Arteriosclerosis
Mod/Severe vs Mild/None
HS Yes vs No

Moderate vs No
AOR (95%CI)
1.14 (0.89-1.46)

Mild vs No

0.80 (0.38-1.70)

0.71 (0.38-1.33)

0.71 (0.61-0.83)

0.77 (0.68-0.88)

0.83 (0.73-0.93)

1.17 (0.47-2.94)

0.91 (0.33-1.76)

0.84 (0.42; 1.75)

43.95 (12.00-163.98)

17.69 (7.63-44.10)

3.58 (1.66-7.70)

3.52 (1.04-12.87)
1.10 (0.16-7.54)
1.61 (0.52-3.98)

1.53 (0.55-4.14)
0.84 (0.28-2.53)
1.50 (0.67-3.15)

1.51 (0.63-3.63)
1.20 (0.52-2.77)
1.14 (0.56-2.20)

2.03 (0.80-5.54)

1.14 (0.66-2.75)

1.54 (0.84-2.93)

0.74 (0.28-2.19)
8.78 (2.25-33.28)

0.96 (0.33-1.74)
5.96 (1.89-20.86)

0.98 (0.40-1.82)
1.34 (0.43-4.03)

0.68 (0.51-0.92)
1.98 (0.75-5.19)

NACC (n=981)

1.24 (0.99-1.54)

AOR (95%CI)

Age at death (5yr increase)

0.57 (0.48-0.67)

0.69 (0.60-0.79)

0.88 (0.77-1.00)

Sex

1.14 (0.65-2.02)

0.79 (0.49-1.29)

0.79 (0.50-1.25)

Education

0.82 (0.74-0.89)

0.81 (0.75-0.89)

0.86 (0.80-0.92)

APOE ε4 allele ≥1 vs 0

1.70 (0.95-3.06)

2.17 (1.31-3.58)

1.55 (0.96-2.50)

26.18 (12.07-56.82)

14.48 (8.38-25.02)

3.93 (2.38-6.50)

4.32 (2.07- 8.99)
0.65 (0.19-2.22)
2.54 (1.37- 4.68)

3.36 (1.75-6.44)
1.53 (0.62-3.82)
2.23 (1.30-3.82)

2.23 (1.19-4.18)
0.96 (0.51-1.83)
2.52 (1.51-4.21)

Braak NFT stage
(V to VI) vs (I to IV)
TDP-43 Yes vs No

Aβ Yes vs No
α-synuclein Yes vs No
Atherosclerosis
>50% vs <50% occluded
1.65 (0.90-3.03)
1.02 (0.61-1.72)
0.80 (0.50-1.30)
Arteriosclerosis
Mod/Severe vs Mild/None
3.05 (1.69-5.49)
1.92 (1.18-3.12)
1.75 (1.11-2.75)
HS Yes vs No
2.41 (0.95-6.16)
1.37 (0.60-3.13)
2.56 (1.11-5.93)
No Decline group was the reference; Abbreviations: AOR, adjusted odds ratio; CI, 95 %
confidence intervals; APOE, Apolipoprotein E; Aβ, Amyloid-β; TDP, transactive response DNA
binding protein 43 kDa; NFT, Neurofibrillary tangle; HS, Hippocampal Sclerosis.
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Table 3.8: Multinomial Logistic Regression based on Complete Case Analysis to
Estimate Adjusted Odds Ratios (AOR) of Membership in a Group with Cognitive
Decline vs. No Decline Within Cohorts. Results are Based on Models Fully Adjusted for
all Variables Listed
Variable

UK-ADRC
Age at death (5yr increase)
Sex Female vs Male
Education
APOE ε4 allele ≥1 vs 0
Braak NFT stage
(V to VI) vs (I to IV)
TDP-43 Yes vs No
Aβ Yes vs No
α-Synuclein Yes vs No
Atherosclerosis
>50% vs <50% Occluded
Arteriosclerosis
Mod/Severe vs Mild/None
HS Yes vs No

Accelerated vs No

Moderate vs No

Mild vs No

AOR (95%CI)
0.68 (0.44 - 0.90)
2.04 (0.63 – 6.59)

1.26 (0.97 - 1.64)

1.24 (98 - 1.57)

0.58 (0.26 -1.32)

0.60 (0.30 – 1.21)

0.70 (0.58 – 0.84)

0.79 (0.68 - 0.91)

0.82 (0.72 – 0.94)

0.83 (0.28 - 2.51)

1.05 (0.45 - 2.41)

0.96 (0.45 - 2.03)

35.92 (8.13-158.13)

19.26 (7.47 - 49.66)

3.18 (1.37 - 7.42)

4.79 (1.08 - 21.34)
1.82 (0.15 - 22.63)
1.71 (0.57 - 5.10)

2.13 (0.67 - 6.79)
0.69 (0.22, 2.22)
1.39 (0.57 - 3.23)

2.61 (0.95 - 7.18)
1.50 (0.60, 3.75)
0.89 (0.41, 1.94)

6.44 (1.85 - 22.48)

1.43 (0.65 - 3.18)

1.99 (1.01 - 3.94)

0.58 (0.18 - 1.82)
4.26 (0.89 - 21.26)

0.79 (0.34, 1.84)
2.85 (0.78 - 10.38)

0.87 (0.42, 1.79)
0.81 (0.24 - 2.71)

NACC

AOR (95%CI)

Age at death (5yr increase)

0.53 (0.44 - 0.64)

0.67 (0.58 - 0.78)

0.85 (0.74 - 0.98)

0Sex Female vs Male

1.15 (0.61 - 2.14)

0.83 (0.50 – 1.38)

0.88 (0.54 - 1.41)

Education

0.85 (0.77 – 0.95)

0.82 (0.75 – 0.89)

0.88 (0.82 – 0.95)

APOE ε4 allele ≥1 vs 0

1.73 (0.92 - 3.25)

2.07 (1.23 - 3.48)

1.56 (0.95 - 2.56)

28.45 (11.67-69.35)

15.40 (8.71 - 27.21)

3.48 (2.09- 5.81)

4.18 (1.91 - 9.13)
0.98 (0.17 - 5.55)
2.34 (1.20 - 4.55)

3.20 (1.66 - 6.18)
1.38 (0.50 - 3.78)
2.16 (1.23 - 3.79)

2.11 (1.12 - 4.00)
0.81 (0.41 - 1.61)
2.62 (1.54 - 4.48)

1.97 (1.01 - 3.82)

1.08 (0.63 - 1.86)

0.97 (0.58, 1.59)

3.00 (1.58 - 5.70)
2.13 (0.78 - 5.75)

1.95 (1.17 - 3.25)
2.07 (0.87 - 4.92)

1.88 (1.17 - 3.03)
1.31 (0.57 - 3.03)

Braak NFT stage
(V to VI) vs (I to IV)
TDP-43 Yes vs No
Aβ Yes vs No
α-synuclein Yes vs No
Atherosclerosis
>50% vs <50% occluded
Arteriosclerosis
Mod/Severe vs Mild/None
HS Yes vs No

Results are from Multinomial logistic regression models, No Decline group was the
reference. Abbreviations: AOR, adjusted odds ratio; CI, 95 % confidence intervals;
APOE, Apolipoprotein E; Aβ, Amyloid-β; TDP, transactive response DNA binding
protein 43 kDa; NFT, Neurofibrillary tangle; HS, Hippocampal Sclerosis.
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Figure 3.4: Distribution of Neuropathology Combinations by Trajectory Groups
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Abbreviations: ADNC, Alzheimer’s disease neuropathologic change; No ADNC, Tau
alone or Tau +CVD or Tau +TDP-43; Aβ, Amyloid-β; TDP, transactive response DNA
binding protein 43 kDa; QMP, quadruple misfolded proteins, α-syn, α-synuclein; CVD,
presence of at least one of the three: Atherosclerosis(>50% Occluded), Arteriosclerosis
(Moderate/Severe) and presence of Infarcts/Lacunes.
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Figure 3.5: Distribution of Neuropathology Combinations by Trajectory Groups
Among Participants Who Started as Cognitively Normal at Baseline
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Abbreviations: ADNC, Alzheimer’s disease neuropathologic change; No ADNC, Tau
alone or Tau +CVD or Tau +TDP-43; Aβ, Amyloid-β; TDP, transactive response DNA
binding protein 43 kDa; QMP, quadruple misfolded proteins, α-syn, α-synuclein; CVD,
presence of at least one of the three: Atherosclerosis(>50% Occluded), Arteriosclerosis
(Moderate/Severe) and presence of Infarcts/Lacunes.
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Figure 3.6: Random Forest Results Indicate the Strength of Association for Each
Variable With Overall Trajectory Membership Within Each Cohort

Variables ranked based on Mean Decrease Accuracy.
Abbreviations: NFT, Neurofibrillary tangle; APOE, Apolipoprotein E; Aβ, Amyloid-β;
TDP-43, transactive response DNA binding protein 43 kDa; HS, Hippocampal
Sclerosis; CAA, Cerebral amyloid angiopathy.
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CHAPTER FOUR
Cancer history associates with a lower burden of dementia and Alzheimer’s-type
neuropathology in autopsied research volunteers
Abstract
Background
Cancer and Alzheimer’s disease (AD) are common diseases in aging populations.
Intriguingly, prior research has reported a lower incidence of AD dementia among
individuals with a history of cancer. The current study was conducted to investigate the
association of cancer history with neuropathological and cognitive features.
Methods
Data were drawn from elderly, longitudinally evaluated participants in a communitybased cohort study of aging and dementia who came to autopsy at the University of
Kentucky Alzheimer’s Disease Research Center (UK-ADRC). The UK-ADRC data were
linked to the Kentucky Cancer Registry (KCR), which is a population-based state cancer
surveillance system, to obtain cancer-related data. We examined the relationship between
cancer history and neuropathological features and clinical diagnoses using inverse
probability weighting to address confounding and selection bias. We investigated the
relation between 20 putative risk single nucleotide polymorphisms that are associated
with AD and cancer history.
Results
Included participants (n=785) had a mean (±SD) age of death of 83.8 (±8.6) years; 60.1%
were female. History of cancer was ascertained in 190 (24.2%) participants. The
prevalence of at least one APOE ε4 allele was lower among participants with cancer
history compared to cancer-free participants (32.6% vs 42%). Participants with cancer
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history had significantly lower odds of MCI/Dementia at the last UK-ADRC visit, as well
as lower odds of Braak neurofibrillary tangle stages III/IV (OR=0.52; 95%CI, 0.34, 0.79;
P = 0.0147) and V/VI (OR=0.38; 95%CI, 0.26, 0.55, P < 0.0001) vs. 0/I/II. Cancer
history was also associated with reduced odds of moderate/frequent neuritic plaques,
moderate/frequent diffuse plaques, and moderate/frequent cerebral amyloid angiopathy.
TDP-43, α-synuclein, and cerebrovascular pathologies were not associated with cancer
history. The investigation of AD-associated genes showed that history of cancer was
inversely associated with APOE ε4 carrier status, and positively associated with T allele
of SNP rs11136000 located in the CLU gene on chromosome 8.
Conclusion
In this study, we showed that cancer history was associated with a lower burden of AD
pathology and have reduced burden of clinical dementia. These findings provide an
additional basis of support for prior epidemiological research reporting a protective
association between cancer and AD-type dementia.
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Introduction
Cancer and Alzheimer’s disease (AD) are common chronic diseases in aging
populations. In the United States, over 5 million people currently have dementia, and
its prevalence is expected to grow to 13.8 million by 2050.25 Both cancer and AD have
high morbidity and mortality and are leading causes of death among older adults.108
Cancer and AD share many reported risk factors, including age, education,
sedentary behavior, smoking, and diet.109,110 Yet, several studies37,38,111-119 including a
Mendelian randomization study36 and meta-analysis studies35,120,121 have reported a
lower incidence of AD, Parkinson’s disease, and other neurodegenerative disorders
among individuals with a history of cancer compared with cancer-free controls. One
study reported that the risk of dementia in patients with cancer was 21% lower
compared to matched cancer-free controls; the risk of dementia was also lower in the
cancer group prior to the diagnosis of cancer.118 Another study reported that older
individuals who developed cancer had better memory and slower memory decline than
did similarly aged individuals who remained cancer-free.122 A simulation study showed
that the competing risk of death and selective survival after cancer could not fully
explain the inverse cancer‐dementia association.123 In contrast, one large Danish study
reported that the inverse association between cancer and AD is small and diminishes
over time.124
While autopsy findings have been not reported extensively, the inverse
association of cancer and AD was first suggested by a cross-sectional autopsy
study.40A recent another autopsy-based study showed that individuals with a history of
cancer have reduced odds of developing clinical AD and a lower burden of
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neurofibrillary tangle deposition compared to individuals with no history of cancer, but
similar levels of amyloid-β (Aβ).39 No other neurodegenerative pathologies have been
reported in prior literature.
Prior research suggests that a matrix of shared genetic factors may confer risks
of cancer and neurodegenerative disease in opposing directions.125,126 For example, the
apolipoprotein E (APOE) gene is the foremost genetic risk-contributing factor for AD,
with ≥ 1 ε4 allele conferring increased risk.127,128 Yet, very few studies examining the
association between cancer and AD have accounted for APOE ε4 carrier
status.39,112,129,130 While on the contrary, the APOE ε4 has been suggested to have a
protective role in some cancers.131,132
Though several studies have examined the association of cancer and clinical
outcomes of AD and dementia, the relation between cancer and AD is not well
understood, but if the inverse association is real, it may lead to new preventive
therapies for AD. The objective of the current study is to evaluate the relationships
between cancer history, AD pathology and other neuropathologic changes, final
syndromic cognitive diagnosis, as well as the association of APOE ε4 and other single
nucleotide polymorphisms (SNPs) known to be associated with AD.
Methods
Study participants
Data were drawn from the community-based cohort study of aging and dementia
at the UK-ADRC.60,133 All included participants were enrolled from 1984-2017 and were
≥ 60 years at death. The University of Kentucky Institutional Review Board approved all
study procedures and all participants provided written informed consent.
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Cancer ascertainment
The Kentucky Cancer Registry (KCR) is a population-based central cancer
registry for the Commonwealth of Kentucky.24 KCR is part of the National Cancer
Institute's Surveillance, Epidemiology, and End Results (SEER) program, regarded to be
among the most comprehensive and accurate cancer registries in the world.48 Kentucky
law requires all health care facilities that either diagnose or treat cancer patients, as well
as freestanding treatment centers, non-hospital (private) pathology laboratories, and
physician offices to report every case of cancer to KCR.54 KCR started collecting
uniform, high-quality data in 1995, so we excluded UK-ADRC participants who died
before 1995.54
The UK-ADRC autopsy data were linked to KCR data to identify cancer cases
occurring in Kentucky from 1995 - 2017 and to acquire cancer-specific data on diagnosis,
stage, treatment, and year at diagnosis. For the current study, only the first primary
diagnosis identified by International Classification of Disease codes for Oncology 3rd
Edition (ICD-O-3)134 was considered a cancer case (i.e., each participant can count as
only one cancer case but may have had multiple cancer diagnoses). The participants with
an ICD code for cancer were considered as 1=cancer history and 0=no cancer
history/cancer-free.
Cancer stage at diagnosis was categorized by the Summary Stage 2000 as in-situ
(non-invasive malignant tumor), localized (tumor is confined to the organ of origin),
regional (tumor has spread by direct extension to immediately adjacent tissues, organs, or
lymph nodes) and distant (a tumor that has spread beyond the immediately adjacent
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tissues and has developed secondary or metastatic tumors).24 Treatment categorized into
3 levels as: ‘No treatment’, ‘Surgery or Chemotherapy and with or without
Radiotherapy’, and ‘Surgery with Radiotherapy and with or without other therapy’.24
Additionally, to assess the timing of the cancer diagnosis relative to UK-ADRC
participation, we categorized the cancer cases as ‘diagnosis before ADRC enrollment,’
‘during the ADRC follow-up period,’ or ‘diagnosed after the last recorded ADRC visit.’
Because tobacco use is a leading risk factor for certain types of cancers,135 dementia and
death, we classified cancer cases into smoking-related (oropharynx, esophageal, liver,
stomach, pancreas, lung, colorectal, kidney, and urinary bladder)135 and non-smoking
related cancers.
Neuropsychological testing
Cognitive functions were evaluated on an approximately annual basis as described
previously63,64 with neuropsychological tests including Mini-Mental State Examination
(MMSE),136 Logical Memory Immediate-Recall 137, and Animal Naming Test scores.94
Participants were classified as having normal cognition, mild cognitive impairment
(MCI), impaired cognition (but not MCI), or dementia at each annual visit based on
cognitive test scores, co-participant reports, neurological examination, medical history,
and physical examination.98 Impaired cognition was defined as per the Uniform Data set
(UDS) standard protocol98 and includes mild impairment not suspected to be due to
neurodegenerative or cerebrovascular disease. Normal cognition indicates intact
functional ability98 and performance within expected ranges for age and education on
neurocognitive tests.94 MCI indicates the presence of objective impairment (scores > 1.5
standard deviations below expected mean) in one or more cognitive domains, intact
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global cognition, no or minimal functional impairment, and no evidence of dementia.65
The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
criteria were used to determine dementia status in the UDS.138 Because of the smaller
frequency in the MCI category at the last diagnosis (n=72), cognitive status was
categorized into a binary variable as Normal vs. MCI/Dementia; we excluded participants
with ‘impaired’ last clinical diagnosis (n=16) for analyses of this variable.
Neuropathological assessment
Details of neuropathological assessment at UK-ADRC have been described
previously.133,139,140 Neuropathological assessments were performed blind to clinical
information. Braak neurofibrillary tangle (NFT) stages were categorized as 0/I/II, III/IV,
and V/VI. Consortium to Establish a Registry in Alzheimer’s Disease (CERAD) diffuse
and neuritic plaque ratings were categorized into dichotomous variables as
moderate/frequent vs. none/sparse.141 Transactive response DNA binding protein 43 kDa
(TDP-43) proteinopathy was considered present if TDP-43 inclusion bodies were
detected in the hippocampus, whereas Lewy bodies (α-synuclein) were considered
present if detected in the brain stem, medial temporal lobe, or the neocortex.
In addition to neurodegenerative pathology, cerebrovascular pathology included
measures of cerebral amyloid angiopathy (CAA), categorized as moderate/severe vs.
none/mild, atherosclerosis severity at Circle of Willis (all vessels ≥50% vs. <50%
occluded), any infarcts/lacunes (yes vs. no), and brain arteriolosclerosis (moderate/severe
vs. none/mild). Cerebral atrophy was classified as moderate/severe vs. none/mild.
Additionally, both right and left hippocampi were evaluated for hippocampal sclerosis
(HS); the presence of HS on either side was considered as the presence of HS.
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Covariates
Covariates included age at death, sex (male/female), UK-ADRC follow-up time in
years, education in years, APOE ε4 genotype converted to a dummy indicator for 1 or
more ε4 alleles, self-reported medical history of diabetes (yes/no), hypertension (yes/no),
myocardial infarction, congestive heart failure (yes/no), history of coronary artery bypass
surgery, and history of angioplasty. Figure 4.1 demonstrates relationship between cancer,
cognitive impairment and neuropathological changes as well as associated covariates.
Genetics
Genetic data were obtained from the UK-ADRC database as described
previously,142 and linked to UK-ADRC clinical and neuropathological outcome data. The
quality control methods were performed before and after imputation using TOPMed
Imputation Server.143,144 We used 21 single nucleotide polymorphisms (SNPs) that were
reported to be associated with AD,145 however we could not evaluate SNP rs8093731 (T)
due to small cell sizes. We assumed that the disease followed a dominant mode of
inheritance with penetrance, that is, we categorized 1 or 2 effect alleles as 1.
Statistical analyses
Two-group comparisons of demographic, neuropathological, and clinical
variables for participants with and without a history of cancer were made using t-tests, χ2
tests, and Wilcoxon-Mann-Whitney tests. To examine the association between cancer and
outcomes (neuropathological and clinical diagnosis at the visit before death), we used
binary and multinomial logistic regression models to estimate the adjusted odds ratios
(OR) and 95% confidence intervals (CI). Thirteen dependent variables were evaluated in
separate models. Statistical significance was set at 0.05, and we used the Holm-
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Bonferroni procedure146 to preserve the family-wise Type 1 error rate for multiple
comparisons.
To account for confounding (i.e., shared causes of cancer and neuropathology),
we applied stabilized inverse probability of treatment weights (SIPTW) to the logistic
models147. SIPTW balances the distribution of measured confounding variables in the
exposure groups (here cancer history vs. no cancer history) by creating a “pseudopopulation”147 where the probability of exposure (cancer) is conditionally independent of
the confounding variables.
SIPTW were computed by fitting a logistic regression model to the data where the
measured confounders age at death, sex, education, polynomial terms for age at death,
education, and APOE ε4 were independent variables, and cancer history was the
outcome, to obtain the conditional probability of having cancer (if the participant actually
did have cancer) or the conditional probability of not having cancer (if the participant
actually did not have cancer). The inverse of these conditional probabilities form the
weight denominators. To stabilize the weights, the marginal probability of cancer (for
those with cancer history) or no cancer (for those without cancer history) was multiplied
by the inverse conditional probabilities. Because the application of the weights can cause
underestimates of parameter variance, we used robust standard errors. Adequacy of
covariate balance in the weighted pseudo-population was assessed by examining the
distribution of weighted variables graphically and by standardized mean differences.147
To evaluate the association of cancer with TDP-43 and arteriosclerosis, which had
a higher percentage of missing data due to administrative reasons (TDP-43 was not
recognized as a biomarker of neurodegeneration until 2006, and arteriolosclerosis was not
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systematically evaluated at UK-ADRC until 2002), we used joint stabilized inverse
probability of treatment and censoring weighting.147,148 Stabilized inverse probability of
censoring weighting (SIPCW) was used under the assumption that data are missing at
random. Like SIPTW, SIPCW is based on estimating the inverse of the probability of the
data being observed for each participant in the dataset conditional on their confounders
and cancer history, multiplied by the marginal probability of the data being observed. The
final weights are the product of the SIPCW and SIPTW, which are applied only to the
participants with complete data, who now represent a pseudo-population where the
conditional probability of cancer is independent of the confounders and where the
conditional probability of being included in the observed data is independent of the
confounders and the exposure (“selection without selection bias”)147. The joint weights
were then used in the logistic models where TDP-43 and arteriolosclerosis were the
outcomes, again with robust standard errors. The weighted sample was evaluated for
robustness as described above.
To account for the possibility that dementia cases are overrepresented in the UKADRC due to selection bias, we we repeated all analyses on a restricted cohort of
participants who began follow-up with normal cognition (n=404). To assess the influence
of the timing of cancer diagnoses on the results, we repeated the analyses on a restricted
cohort of participants excluding participants with prevalent cancers (n = 50).
The association of the SNPs and the outcomes of cancer and clinical diagnosis
were evaluated using logistic regression with one SNP at a time along with covariates
(age at death, sex) and weights derived using SIPTW method. As a sensitivity analyses,
seven participants were excluded as ethnic outliers and reran logistic regression along
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with the three principal components (PCs) and covariates The ethnic outliers were
identified by performing principal component analysis (PCA) dimensionality reduction
merged with 1000 Genomes Phase 3 data (Figure 4.2).149 Analyses were conducted in
SAS 9.4 (SAS, Inc., Cary, NC) and Forest plots were created in Stata/SE, version 14.2
(College Station, TX: StataCorp LP); ggplot2 package in R was used to generate the PCA
plot.
Results
The final study sample included 785 autopsied participants with linkage to KCR
(Figure 4.3). The data linkage with KCR identified 190 (24.2%) participants with cancer
history. Participant characteristics are presented in Table 4.1. Overall, the mean
(±standard deviation (SD) UK-ADRC follow-up time was 8.8 ±5.6 years (i.e., study
baseline to death), the mean age at study entry was 75.1 ±8.2, the mean age of death was
83.8 ±8.6 years, more than 60.1% of the sample (n=472) were females, and 39.4% had at
least one ε4 allele of the APOE genotype (n = 312). Participants with cancer history had
significantly more years of education (15.8 vs. 14.8 years, P <0.001) and a lower
prevalence of at least one APOE ε4 allele (32.6% vs. 42.0%, P = 0.0063) compared to
cancer-free participants. Participants with cancer history had a higher prevalence (45.8%)
of cognitively normal diagnosis at the last UK-ADRC assessment vs 23.5% of the cancerfree participants had a normal diagnosis, whereas MCI/Dementia prevalence (22.6%) was
lower in the cancer history participants vs higher prevalence (48.2%) among the cancerfree participants, P <0.0001). Mean MMSE, Animal Naming, and Logical Memory
Immediate-Recall scores (6 years before death) were higher among the participants with a
cancer history (P <0.0001, P=0.045, and P=0.016, respectively), while closer to death (≤
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2 years before death) only MMSE and Animal Naming scores were significantly higher
among these participants (Table 4.1).
Among the participants who were cognitively normal at baseline (n=404) (Table
4.2), participants with cancer history died younger (mean (SD), 85.3 (7.4)) compared to
the cancer-free participants (mean (±SD) 87.9 ±2.2, P <0.001). Sex, educational
attainment, APOE ε4 allele, and last visit clinical diagnosis were similar among those
with and without cancer. Only MMSE (measured at 6 years before death), and Logical
Memory Immediate-Recall (measured at ≤2 years before death) were significantly
different (P = 0.0050, and P = 0.0289 respectively).
Cancer characteristics by cognitive diagnosis are provided in Table 4.3. At
baseline 50 (26.3%) participants had a history of cancer before enrollment in the UKADRC, while 83 (43.7%) developed cancer during the UK-ADRC follow-up and 57
(30.0%) were diagnosed with cancer after the last visit. Breast cancer was diagnosed in
33 (17.4%) participants, gastrointestinal cancers in 32 (16.8%), lung cancer in 29
(15.2%), while other types of cancers were less common. Non-smoking-related cancers
were diagnosed in 57.4%, and smoking-related in 42.6% of participants. 42.1% had
localized stage of cancer and 60.0% of the participants were treated with a combination
of treatments such as surgery and radiation and with/without other therapies, but not
including chemotherapy. Further, the cancer characteristics were described by cognitive
status.
The neuropathological outcome measures had only a small proportion of missing
data except for TDP-43 (43.3%) and arteriosclerosis (18.5%) (Table 4.4).
Neuropathological characteristics are presented in Table 4.5. Participants with cancer
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history were more likely to have lower frequencies of higher Braak NFT stages (III/IV
and V/VI), moderate/frequent diffuse and neuritic plaques, Lewy bodies, moderate/severe
cerebral atrophy, and moderate/severe CAA. While TDP-43, HS, and cerebrovascular
pathologies were similar in distribution between the two groups. However, participants
who were cognitively normal at baseline, lower frequencies were only seen in the higher
Braak NFT stages (III/IV and V/VI), moderate/severe diffuse plaques, and presence of
infarcts/lacunes among cancer history participants (Table 4.6).
In SIPTW multivariable logistic regression models using SIPTW, history of
cancer was associated with approximately 55% lower odds (OR = 0.45; 95% CI, 0.31,
0.64; P< 0.0001) of MCI/Dementia. Participants with cancer history had an estimated
62% decreased odds (OR=0.38; 95% CI, 0.26, 0.56; P <0.0001) of having Braak NFT
V/VI stages and 48% decreased odds (OR = 0.52; 95% CI, 0.34, 0.79; P = 0.0147) of
Braak NFT III/IV stages vs. Braak NFT 0/I/II stages (Figure 4.4a). Cancer history was
associated with lower odds of moderate/frequent diffuse (OR = 0.53; 95% CI, 0.36, 0.76;
P =0.0013), neuritic plaques (OR = 0.53; 95%CI, 0.37, 0.76; P = 0.0005) and CAA (OR
= 0.57; 95% CI, 0.37, 0.91; P = 0.0165). However, CAA and Braak NFT stage III/IV
were not significant when the Holm-Bonferroni correction was applied. Among the
participants who started as cognitively normal (Figure 4.4b), cancer history was only
significantly associated with Braak NFT stages III/IV (OR= 0.56; 95%CI, 0.34, 0.91; P =
0.0415) and Infarcts/Lacunes (OR=0.57; 95%CI, 0.37, 0.87; P = 0.0080).
Finally, we examined genetic associations with history of cancer and cognitive
diagnosis. Cancer history was associated with lower odds of ≥ 1 APOE ε4 allele
(OR=0.63; 95% CI, 0.44, 0.90; P = 0.0115), while MCI/Dementia was significantly
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associated with higher odds OR=2.73; 95% CI, 1.89, 3.95; P <0.0001). Of the 785
participants included in our study, 393 had SNP data (Table 4.7). Cancer history was
associated with higher odds of the T allele of SNP rs11136000 located in the CLU gene
on chromosome 8, with OR=1.79; 95% CI, 1.07, 3.00; P = 0.0276) while MCI/Dementia
was associated with lower odds, OR=0.46; 95% CI, 0.25, 0.85; P = 0.0131), however
sensitivity analysis using PCs as covariates resulted in similar estimates but a higher Pvalues (P = 0.0457 for cancer history and P = 0.0049 for MCI/Dementia)
Discussion
The current autopsy study based on UK-ADRC elderly participants (N=785) with
and without cancer history supports prior findings that cancer diagnosis is significantly
associated with a lower clinical all-cause dementia diagnosis, as well as a reduced burden
of AD pathology. We also examined the association of cancer history with multiple
neuropathological outcomes, which have not been extensively reported in prior research.
AD pathology, as well as CAA, were notably lower in participants with a cancer history.
These results remained unchanged even with incident cancers. Examination of cognitive
test scores suggested that participants with cancer history had higher cognitive scores
compared to cancer-free participants in the 6 years before death.
The perplexing inverse relationship between cancer and dementia has generated
interest among researchers and has been increasingly reported by multiple
studies.9,35,37,39,111-113,115,117,118,122,124,150 But, to date, only two studies have reported on
the association of cancer and neuropathology.39,40 In the current study, cancer history
participants had lower odds of AD neuropathology (NFT’s, neuritic, and diffuse
plaques), a plausible reason for higher MMSE, Animal Naming cognitive scores and a
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lower percentage with clinical dementia. We did not find any significant association with
the presence of Lewy bodies, TDP-43, other neuropathological disorders, and
cerebrovascular pathologies.
The present study results were generally consistent with the previous
studies. A recent multicenter cohort study found that among individuals with either
mild or isolated cognitive complaints, incident cancer was associated with a
reduced risk (~50%) of dementia, accounting for various biases.129 A retrospective
cohort of 3.5 million elderly veterans, survivors of most cancers had a reduced risk
of AD, but increased risk of the alternative outcomes (non-AD dementia,
osteoarthritis, stroke, and macular degeneration).116 Driver et al., using data from
the Framingham Heart Study, reported that the protective effect of previous cancer
was greater for smoking-related cancers than for non-smoking-related cancers,
accounting for competing risk of mortality.37 While Ording et al., using a
nationwide Danish cohort that included patients with dementia and Parkinson’s
disease, reported lower standardized incidence rate ratios and absolute reduction
cancer risk during 10 years follow-up for AD, vascular dementia, and all-cause
dementia.119 While, in another study, Ording et al. analyzed individuals surviving
cancer >10 years and reported that the standardized incidence rate ratios for
incident diagnoses of AD after stratification by sex, age, and cancer stage,
approached that of the general population.124 Hanson et al., report that modeling
cancer as a time-varying predictor mitigates the inverse relationship between cancer
and AD.151 However, a recently published study using Mendelian randomization to
assess the causal relationship between cancer (data from Genome-Wide Association
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Studies) and Alzheimer’s disease (summary statistics from IGAP), found that
genetically predicted cancer (lung, leukemia, breast), and smoking-related cancers
were associated with lower odds of AD.36
This study results provide additional evidence for the inverse association of
cancer history and AD-type pathology. Both diseases are characterized by a set of
molecular determinants (such as p53, cyclin D, cyclin E, cyclin F, Pin1, and protein
phosphatase 2A (PP2A)) that are either complementarily deregulated or share
remarkably overlapping functional pathways.152 The PIN1 gene (regulates Pin1
enzyme) is overexpressed in certain cancers but is downregulated in AD
pathogenesis and neuronal degeneration.153,154 An experimental study demonstrated
that PIN1 knockout increases Aβ42 production, suggesting that it might favor
amyloidogenic amyloid precursor protein (APP) processing and elevates Aβ42 in an
age-dependent manner.155 Transcription factor p53 (tumor suppressor) is reported to
be downregulated in cancer but inversely upregulated in neurodegenerative
diseases.152,156
APOE ε4 is one of the strongest risk factors for AD neuropathological
changes,127,128 and we found an inverse association of APOE ε4 and cancer history.
We were not able to examine the three common isoforms128 ε2, ε3, and ε4 of the
APOE genotype individually due to small cell sizes. A recent mouse model study
found that animals expressing the human APOE ε4 allele exhibited reduced
melanoma progression and metastasis relative to APOE ε2 mice.157 It is plausible
that interaction of APOE ε4 genotype and Aβ, which plays a key role in aggregation
and clearance and therefore directly influences the development of amyloid plaques,
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cerebral amyloid angiopathy, and subsequent tau-related pathology,158 and maybe
partly responsible for the inverse association of cancer and AD. However, a study
conducted using Alzheimer’s disease Neuroimaging Initiative (ADNI) data found
cancer survivors had a delay in the onset of AD independent of their APOE ε4
status.159
In an additional genetic analysis using 20 SNPs, we found the T allele of
rs11136000 (located on the CLU gene in chromosome 8) had lower odds of
MCI/Dementia. The T allele on this SNP has been reported to associate with a
reduced risk for late-onset AD.145,160 In a review article Foster et al., highlighted the
role of Clusterin in a range of pathologies including cancer, cardiovascular disease,
and neurodegeneration and suggested that the pathways may help to understand its
biological function(s) in association with AD.161 Clusterin protein encoded by the
CLU gene is overexpressed in several metastatic cancer cells, such as colon,
bladder, hepatocellular carcinoma, and renal cell carcinoma.162,163
The inverse association between cancer and AD-type dementia could also be
due to non-biological pathways; for example, a cancer diagnosis may also bring
about healthy lifestyle behavioral changes, such as increased exercise and better
nutrition, which result in healthier brain aging.39 Furthermore, cancer may be less
often be screened and diagnosed in cognitively impaired individuals.124 The role of
survivor bias cannot be ruled out completely; however, a recently published
simulation study demonstrated that selective survival was too small to explain the
observed inverse cancer-dementia link, suggesting other mechanisms drive this
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association.123 In the current study, the average age at death of the participants was
more than 83 years and similar among those with and without cancer.
Lower AD risk in cancer survivors is associated with chemotherapeutic
drugs than those who receive radiation therapy.116 A large study using a populationbased cancer registry found that chemotherapy decreased the risk of AD death in
white women diagnosed with breast cancer at the age of 65 or older.38
Chemotherapeutic drugs such as taxanes are microtubule stabilizers, are
investigated for their role in reducing tau pathology as a treatment for AD and
related tauopathies.164 In the current study, only 15% of the participants with cancer
history received chemotherapy; however, we could not examine the effect of cancer
treatment due to the small sample size.
A major strength of the study is that we linked the UK-ADRC data to the
KCR, unlike other studies the cancer cases are confirmed by pathologists, and not
self-reported. The KCR is a population-based registry, so it is less likely that we
may have missed cancer diagnosis, although it is possible. The longitudinal cohort
at the UK-ADRC with the availability of rich neuropathological data makes this
study unique. Additionally, the availability and adjustment of APOE genotype
status (not been commonly reported by prior research studies) while evaluating
cancer and dementia association.115,118,124 None of the prior research studies have
included multiple aspects of evaluation i.e. clinical diagnosis, longitudinal cognitive
scores, genetic, and neuropathological evaluations in reporting the association of
cancer and dementia. Furthermore, we used inverse probability weighting to
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examine the association to balance the measured confounding variables and
multiple biases that are integral to observational and autopsy studies.148
The study had some limitations. Due to the relatively small sample size of
participants with cancer (n=190), we could not investigate site-specific cancers, as
well as the effect of the treatments, received stages of cancer, and comorbid heart
diseases. Some studies have reported cancer chemotherapy treatments to decrease
cognitive functions in cancer survivors,38,130,165 the effect referred to as
“chemobrain.” Furthermore, our study included only participants age ≥ 60 years
enrolled at the UK-ADRC; hence, it is unknown whether the inverse association
would be relevant to the people who died of cancer before the age of 60. Other
limitations are the unavailability of multiple cognitive test scores to examine
specific cognitive domains, as well as the relatively limited generalizability of
autopsy cohorts due to the nature of these studies.
Conclusion
In conclusion, a persistent inverse association between cancer and dementia
was evident in our study, and this study adds neuropathological evidence to the
existing literature on epidemiological cohorts. We identified a possible mechanism
for the inverse association with AD-type pathology, with genetically driven
pathways acting in opposite directions, but the association of APOE ε4 and CLU
with cancer needs further evaluation.
Funding
This work was funded by National Institute on Aging grant P30 AG028383
(PI: Linda Van Eldik). Additional support came from National Institute on Aging
R01 AG038651 (PI: Richard J. Kryscio).
90

Figure 4.1: Directed acyclic graph demonstrating the relationship between cancer, cognitive impairment, and
neuropathological changes as well as associated covariates

Age
Sex
Education
Lifestyle factors
Diet/Nutrition
Psychosocial factors

Medical comorbidities

Genetic factors

Cancer treatment
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Cancer history
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Figure 4.2: The First and Second Principal Components Plot Along With 1000
Genome Reference Samples

Black dots indicate individuals in this study. Gray arrow pointing to the seven participants, who
were excluded in the sensitivity analysis. AFR = African; AMR = Admixed American; EAS =
East Asian; EUR = European; SAS = South Asian
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Figure 4.3: Participant Inclusion Flow Diagram
Total Brain Bank Autopsies
(UK-ADRC)
n=884

List sent to
Kentucky Cancer Registry (KCR)
n= 819

Exclusions
Died < 60 years of age
n=34

Cases included
n= 785
*KCR population-based state surveillance data available beginning in 1995
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Table 4.1: Demographic and clinical characteristics of autopsied UK-ADRC participants
by cancer history with known cancer status and available neuropathological data
Variable
Age at baseline, mean (SD), y
Age at death, mean (SD) y
Follow-up time, mean (SD), y
Female sex
Race (White)
Education, y mean (SD)
APOE ε4 allele
None
≥ 1 Alleles
Baseline clinical diagnosis
Normal
MCI /Dementia
Last Clinical Diagnosis**
Normal
MCI /Dementia
Hypertension (present)
Diabetes (present)
Myocardial Infarction (present)
Congestive heart failure (present)
Angioplasty (present)
Coronary artery bypass
surgery(present)

All
participants
(n=785)
75.1 (8.2)
83.8 (8.6)
9.2 (5.5)
472 (60.1)
775 (98.7)
15.0 (3.2)

Cancer
History
(n=190)
74.7 (7.5)
84.5 (7.8)
10.0 (5.9)
108 (56.8)
183 (96.3)
15.8 (3.0)

No Cancer
History
(n=595)
75.3 (8.3)
83.6 (8.9)
8.9 (5.4)
364 (61.2)
603 (98.7)
14.8 (3.2)

Pvalue*
0.345
0.116
0.019
0.371
0.057
<0.001

429 (54.7)
312 (39.8)

123 (64.7)
62 (32.6)

306 (51.4)
250 (42.0)

0.006

404 (51.5)
330 ( 42.0)

144 (75.8)
43(22.6)

260 (43.7)
287 (48.2)

<0.001

227 (31.0)
539 (68.7)
429 (54.7)
104 (13.3)
97 (12.4)
101 (12.9)
52 (6.6)

87 (45.8)
95 (50.0)
118 (62.1)
26 (13.7)
21 (11.1)
25 (13.2)
14 (7.4)

140 (23.5)
444 (74.6)
311 (52.3)
78 (13.1)
76 (12.8)
76 (12.8)
38 (6.4)

<0.001
0.167
0.741
0.287
0.766
0.889

60 (7.6)

14 (7.4)

46 (7.7)

0.603

20.0(9.9)
25.3 (6.7)
13.4 (6.6)
17.0 (5.7)

24.0 (7.9)
27.5 (4.1)
14.8 (6.3)
17.9 (5.4)

18.4 (10.3)
24.3 (7.4)
12.6 (6.7)
16.5 (5.9)

<0.001
<0.001
0.002
0.046

10.9 (6.3)

11.4 (5.8)

10.6 (6.5)

0.309

13.5 (5.13)

14.4 (5.0)

13.0 (5.2)

0.016

Cognitive test scores, mean (SD)
MMSE, ≤2 years of death †
MMSE, 6 years prior to death††
Animal naming, ≤2 years of death‡
Animal naming, 6 prior to death‡‡
Logical Memory (I), ≤2 years of death
₡
Logical Memory (I), 6 prior to death
₡₡

*Comparisons are Cancer history vs. No cancer history. **n= 766, participants with Impaired and missing
clinical diagnosis are not reported here. Missing data are reported in Table 4.4.
† Cancer history n=155, No Cancer history n=382;†† Cancer history n=127, No Cancer history n=275
‡ Cancer history n=135, No Cancer history n=249; ‡ ‡ Cancer history n=121, No Cancer history n=219;
₡ Cancer history n=125, No Cancer history n=213; ₡₡ Cancer history n=116, No Cancer history n=197;

Abbreviations: UK-ADRC =University of Kentucky Alzheimer’s Disease Research Center;
APOE ε4 allele = apolipoprotein ε4 allele; MMSE= Mini-Mental State Examination; Logical
Memory (I)= Logical Memory Immediate Recall. SD=Standard deviation.
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Table 4.2: Demographic and clinical characteristics of autopsied UK-ADRC participants
who started as cognitively normal at baseline with known cancer status and available
neuropathological data.

Age at baseline

All
participants
(n=404)
75.6 (7.3)

Cancer
History
(n=144)
74.1 (6.9)

No History
of cancer
(n=260)
76.4 (7.4)

Age at death, y mean (SD)

87.0 (7.4)

85.3 (7.4)

87.9 (2.2)

Female sex
Education, y mean (SD)

253 (62.6)
16.0 (2.6)

84 (58.3)
16.3 (2.8)

169 (65.0)
15.8 (2.5)

APOE ε4 allele
-/≥ 1 ε4 Alleles

276 (68.3)
122 (30.2)

102 (70.8)
41 (28.5)

174 (66.9)
81 (31.2)

Last Clinical Diagnosis**
Normal
MCI /Dementia

226 (58.9)
166 (41.1)

86 (62.8)
51 (37.2)

140 (54.9)
115 (45.1)

0.1326

Hypertension (present)

237 (58.7)

85 (59.0)

152 (58.5)

0.2423

Diabetes (present)
Myocardial Infarction (present)

56 (13.9)
59 (14.6)

16 (11.1)
16 (11.1)

40 (15.4)
43 (16.5)

0.0854

Congestive heart failure (present)

76 (18.8)

20 (13.7)

56 (21.5)

Angioplasty (present)

32 (7.9)

11 (7.6)

21 (8.1)

0.0166
0.5679

Coronary artery bypass surgery(present)

35 (8.7)

9 (6.3)

26(10.0)

0.0646

Cognitive test scores (last visit) mean (SD)
MMSE, ≤2 years of death †
25.1 (6.8)

26.3 (5.8)

24.5 (7.3)

MMSE, 6 years prior to death††

28.2 (2.5)

28.6 (2.7)

28.0 (2.7)

0.0050
0.2118

Animal Naming test, ≤2 years of death‡
Animal Naming test, 6 prior to death‡‡

15.0 (6.2)
17.8 (5.4)

15.6 (6.0)
18.2 (5.1)

14.5 (6.2)
17.6 (5.5)

0.1440
0.1674

Logical Memory (I), ≤2 years of death ₡

12.6 (5.4)

12.2 (5.4)

12.8 (5.3)

0.4353

Logical Memory (I), 6 prior to death ₡₡

14.3 (4.6)

15.3 (4.5)

13.8 (4.6)

0.0289

Variable

Pvalue*
0.0021
0.0004
0.1847
0.1193
0.5207

0.0377

*Comparisons are Cancer history vs. No cancer history
** n= 392, 12 participants with Impaired and missing Clinical diagnosis were excluded
† Cancer history n=122, No Cancer history n=207; †† Cancer history n=109, No Cancer history n=191
‡ Cancer history n=115, No Cancer history n=179; ‡ ‡ Cancer history n=109, No Cancer history n=182
₡ Cancer history n=108, No Cancer history n=166; ₡₡ Cancer history n=106, No Cancer history n=177

Abbreviations: UK-ADRC, University of Kentucky Alzheimer’s Disease Research Center; APOE
ε4, apolipoprotein ε4 allele; MMSE, Mini-Mental State Examination score; Logical Memory (I),
Logical Memory- Immediate recall test.
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Table 4.3: Distribution of cancer case characteristics by final cognitive status
Cancer characteristics
Cancer diagnosis in relation to ADRC Enrollment
period
Diagnosis before ADRC enrollment
Diagnosis during ADRC follow-up
Diagnosis after last ADRC visit
Cancer types
Breast
Colorectal/stomach/peritoneal
/Pancreatic/Liver/Gallbladder
Lung
Prostate
Bladder/Kidney
Basal cell carcinoma/soft/connective tissue
Miscellaneous†
Unspecified Primary
Oropharyngeal/Esophageal
Ovary/ Uterus/Endometrium
Smoking related
Smoking-related cancers*
Not smoking-related cancers
Cancer Stage
In-situ
Localized
Regional
Distant
Unknown/Unstageable
Cancer Treatment
No treatment
Chemo or Surgery and with/without Radiation
therapy
Surgery and Radiation and with/without Other
therapy

All Cancer
Cases
(n=190)

Normal**
(n= 87)

MCI /
Dementia**
(n=95)

50 (26.3)
83 (43.7)
57 (30.0)

16 (18.4)
42 (48.3)
29 (33.3)

32 (33.7)
35 (36.8)
28 (29.5)

33 (17.4)

9 (10.3)

21 (22.1)

32 (16.8)
29 (15.2)
26 (13.7)
18 (9.5)
16 (8.4)
10 (5.3)
10 (5.3)
8 (4.2)
8 (4.2)

16 (18.4)
21 (24.1)
9 (10.3)
6 (6.9)
8 (9.2)
6 (6.9)
5 (5.7)
3 (3.4)
3 (3.4)

15 (15.8)
6 (6.3)
15 (15.8)
10 (10.5)
7 (7.4)
3 (3.2)
5 (5.3)
5 (5.3)
5 (5.3)

81 (42.6)
109 (57.4)

47 (49.5)
48 (50.5)

34 (35.8)
61 (64.2)

18 (9.5)
80 (42.1)
28 (14.7)
40 (21.1)
24 (12.6)

3 (3.5)
30 (34.5)
17 (19.5)
25 (28.7)
12 (13.8)

13 (13.7)
46 (48.4)
10 (19.5)
15 (15.8)
11 (11.6)

47 (24.7)

18 (20.7)

8 (8.4)

29 (15.3)

23 (26.4)

22 (23.2)

114 (60.0)

46 (52.9)

65 (68.4)

**8 participants with impaired diagnosis were excluded from the stratified analysis
*Smoking-related cancers (Lung, Bladder, oropharyngeal, pancreas, Stomach, Colorectal, Liver,
Esophageal, Kidney); † Miscellaneous cancers: Brain, spinal cord, acoustic nerve, lymph nodes,
cardiac; ADRC- Alzheimer’s Disease Research Center; chemo- chemotherapy
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Table 4.4: Frequency of Missing Data
Variable

All

Education
Race
APOE ε4 allele

No Cancer history

Clinical Diagnosis (Baseline)

18 (2.29)
9 (1.15)
44 (5.6)
51 (6.50)

Cancer history
No. (%)
1 (0.53)
0
5 (2.6)
3 (1.6)

Clinical Diagnosis Either
missing/unknown or Impaired (last
assessment)
Hypertension
Diabetes
Myocardial Infarction
Congestive heart failure
Angioplasty
Coronary artery bypass surgery
Braak NFT stage
Diffuse plaques
Neuritic plaques
TDP-43 inclusion bodies
Lewy bodies
Hippocampal sclerosis
Atherosclerosis
Arteriosclerosis
Cerebral atrophy
Cerebral amyloid angiopathy
Argyrophilic grain disease

19 (2.4)
138 (17.6)
188 (23.9)
181 (23.1)
172 (21.9)
203 (25.9)
226 (28.8)
18 (2.3)
1 (0.1)
1 (0.1)
340 (43.3)
5 (0.6)
10 (1.3)
15 (1.9)
145(18.5)
10 (1.3)
18 (2.3)
29 (3.7)

8 (4.2)
23 (12.1)
33 (17.4)
33 (17.4)
31 (16.3)
38 (20.0)
44 (23.2)
1 (0.5)
0
0
66 (34.7)
3 (1.6)
4 (2.1)
1 (0.5)
16 (8.4)
0
2 (1.1)
5 (2.6)

11 (1.9)
115 (19.3)
155 (26.1)
148 (24.9)
141 (23.7)
165 (27.7)
182 (30.6)
17 (2.9)
1 (0.2)
1 (0.2)
274 (46.1)
2 (0.3)
6 (1.01)
14 (2.4)
129 (21.7)
10 (1.7)
16 (2.7)
24 (4.0)

17 (2.9)
9 (1.51)
39 (6.6)
48 (8.1)

Abbreviations: APOE ε4, apolipoprotein ε4 allele; NFT, neurofibrillary tangle; TDP-43,
transactive response DNA-binding protein 43 kDa.
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Table 4.5: Neuropathological Characteristics of Autopsied UK-ADRC Participants by
Cancer History (n=785)
Variable
Brain weight, grams
mean (SD)
Braak NFT stage
0/I/II
III/IV
V/VI
Diffuse Plaques
None/Sparse
Moderate/Frequent
Neuritic Plaques
None/Sparse
Moderate/Frequent
Lewy bodies (present)
TDP-43 (present)
Cerebral atrophy
None/Mild
Moderate/Severe
Hippocampal Sclerosis
(present)
CAA
None/Mild
Moderate/severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded
Arteriosclerosis
None/Mild
Moderate/Severe
Brain Infarcts/Lacunes
(Present)
AGD (present)

All
Participants
(n=785)

Cancer
History
(n=190)

No Cancer
History
(n=595)

P-value

1158.8 ±154.2

1187.6 ±163.9

1149.9 ±150.1

0.002

247 (31.5)
133 (16.9)
387 (49.3)

95 (50.3)
33 (17.5)
61 (32.3)

152 (26.3)
100 (17.3)
326 (56.4)

170 (21.7)
614 (66.8)

63 (33.2)
127 (66.8)

107 (18.0)
448 (82.0)

255 (32.5)
529 (67.5)
264 (33.9)
165 (20.0)

90 (47.4)
100 (52.6)
51 (26.8)
39 (20.5)

165 (27.8)
316 (72.2)
213 (35.9)
126 (20.3)

521 (67.2)
254 (32.8)

144 (75.8)
46 (24.2)

377 (63.4)
208 (35.0)

0.0038

133 (16.9)

27 (14.2)

106 (17.8)

0.2724

553 (70.5)
214 (27.3)

153 (80.5)
35 (18.4)

400 (67.4)
179 (29.8)

0.0011

370 (47.1)
400 (51.0)

91 (47.9)
98 (51.6)

279 (46.9)
302 (50.8)

0.9757

495 (63.1)
145 (18.5)

131 (69.0)
43 (22.6)

364 (61.2)
102 (17.1)

0.4476

348 (44.3)
113 (15.0)

78 (41.1)
25 (13.2)

270 (45.4)
88 (14.8)

0.2961
0.5292

<0.0001

<0.0001
<0.0001
0.0294
0.1267

Missing data are reported in Table 4.4.
Abbreviations: NFT, neurofibrillary tangle; CAA, Cerebral amyloid angiopathy; AGD,
Argyrophilic grain disease; TDP-43, transactive response DNA-binding protein 43 kDa.
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Table 4.6: Neuropathological Characteristics of Autopsied UK-ADRC Participants Who
Started as Cognitively Normal at Baseline by Cancer History (n=404)
Variable
Brain weight, grams, mean
(SD)
Braak NFT stage
0/I/II
III/IV
V/VI
Diffuse Plaques
None/Sparse
Moderate/Frequent
Neuritic Plaques
None/Sparse
Moderate/Frequent
Lewy bodies (present)
TDP-43 (present)
Cerebral atrophy
None/Mild
Moderate/Severe
Hippocampal Sclerosis
(present)
Cerebral amyloid angiopathy
None/Mild
Moderate/severe
Atherosclerosis
<50% Occluded
≥ 50% Occluded
Arteriosclerosis
None/Mild
Moderate/Severe
Brain Infarcts/Lacunes
(present)
AGD (present)

All
Participants
(n=404)

Cancer
History
(n=144)

No Cancer
History
(n=260)

1191.6 ±137.3

1204.4 ±163.9

1149.9 ±150.1

193 (47.8)
111 (27.5)
94 (23.3)

84 (58.3)
29 (20.1)
30 (20.8)

109 (41.9)
82 (31.5)
64 (24.6)

131 (32.4)
273 (67.6)

57 (39.6)
87 (60.4)

74 (28.5)
186 (71.5)

196 (48.5)
208 (51.5)
94 (23.3)
82 (20.3)

79 (54.9)
65 (45.1)
31 (21.5)
28 (19.4)

117 (45.0)
143 (55.0)
63 (24.2)
54 (20.8)

331 (81.9)
69 (17.1)

121 (84.0)
23 (16.0)

210 (80.8)
46 (17.7)

57 (14.1)

18 (12.5)

39 (15.0)

320 (79.2)
83 (20.5)

201 (77.3)
59 (22.7)

119 (82.6)
24 (16.7)

0.1605

190 (47.0)
210 (52.0)

70 (48.6)
73 (50.7)

120 (46.2)
137 (52.7)

0.6647

264 (65.4)
83 (20.5)

99 (68.8)
43 (22.9)

165 (63.5)
50 (19.2)

0.7116

206 (51.0)
68 (16.8)

59 (41.0)
20 (13.9)

147 (56.5)
48 (18.5)

Pvalue
0.1343
0.0064

0.0222
0.0575
0.5730
0.8213
0.6119
0.5488

0.0027
0.2152

Abbreviations: NFT, neurofibrillary tangle; AGD, Argyrophilic grain disease; TDP-43,
transactive response DNA-binding protein 43 kDa.
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Table 4.7: Weighted odds ratios for neuropathological features (Cancer history vs. No
Cancer history)

Dependent variables
Clinical diagnosis (last visit)
MCI/Dementia vs Normal
Neuropathology
Braak NFT stage
III/IV vs 0/I/II
V/VI vs 0/I/II
Diffuse Plaques
Moderate /Frequent vs
Sparse/Normal
Neuritic Plaques
Moderate/Frequent vs.
Sparse/None
Lewy bodies
Present vs. Absent
TDP-43 inclusion bodies
Present vs. Absent
Cerebral atrophy
Moderate/Severe vs. None/Mild
Hippocampal sclerosis
Present vs. Absent
Cerebral amyloid angiopathy
Moderate/severe vs None/Mild
Atherosclerosis
≥ 50% Occluded vs. <50%
Occluded
Arteriosclerosis
Moderate/Severe vs.
None/Mild
Brain Infarcts/Lacunes
Present vs. Absent
Argyrophilic grain disease
Present vs. Absent

Weighted
OR (95% CI)
N= 785*

Weighted
OR (95% CI)
N=735**

Weighted
OR (95% CI)
N= 404***

0.47 (0.32 - 0.68)

0.35 (0.23 – 0.54)

0.90 (0.59 – 1.41)

0.52 (0.37 - 0.86)*
0.38 (0.26 - 0.55)

0.49 (0.28 - 0.85)*
0.31 (0.19 - 0.51)

0.55 (0.32 - 0.95)*
0.77 (0.44 - 1.31)

0.53 (0.36 - 0.78)

0.47 (0.31 - 0.73)

0.71 (0.16 – 1.11)

0.52 (0.36 - 0.75)

0.50 (0.33 – 0.75)

0.82 (0.54 – 1.26)

0.74 (0.49 - 1.11)

0.74 (0.47 – 1.16)

0.86 (0.52 – 1.42)

0.79 (0.48 - 1.30)

0.80 (0.47 – 1.39)

0.71 (0.41 – 1.25)

0.76 (0.50 - 1.14)

0.65 (0.39 – 1.10)

1.12 (0.64 -1.96)

0.84 (0.50 - 1.42)

0.81 (0.43 – 1.52)

0.96 (0.51 – 1.78)

0.58 (0.38 - 0.90)†

0.52 (0.30 - 0.91)†

0.82 (0.48 - 1.42)

1.05 (0.73 - 1.50)

0.97 (0.65 – 1.45)

1.16 (0.73 - 1.70)

1.00 (0.66 - 1.54)

0.99 (0.55 – 1.77)

0.96 (0.57 - 1.62)

0.78 (0.55 - 1.12)

0.86 (0.57 - 1.28)

0.57 (0.37- 0.87)

0.92 (0.54 - 1.56)

0.92 (0.50 -1.70)

0.73 (0.40 - 1.31)

* Weighted odds ratios for neuropathological features (Cancer history vs. No Cancer history
** Weighted odds ratios for neuropathological features (Incident Cancer history vs. No Cancer history
*** Weighted odds ratios for neuropathological features (Cancer history vs. No Cancer history) among
participants who started as cognitively normal
†Not significant when multiple comparison p-value was applied.

Abbreviations: NFT, neurofibrillary tangle; CAA, Cerebral amyloid angiopathy; AGD,
Argyrophilic grain disease; TDP-43, transactive response DNA-binding protein 43 kDa.
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Table 4.8: Association of SNPs with Cancer History and Cognitive Status
Cancer vs No cancer

MCI/Dementia vs Normal

CR1 (chr1) rs6656401 (A)

Covariates
+ weights
OR (95% CI)
1.22 (0.76; 1.94)

Covariates + weights Covariates
+PCs
+ weights
OR (95% CI)
OR (95% CI)
1.22 (0.76; 1.95)
0.80 (0.48; 1.34)

Covariates
+ weights +PCs
OR (95% CI)
0.79 (0.47; 1.32)

BIN1 (chr 2) rs6733839 (T)

1.08 (0.66; 1.74)

1.07 (0.66; 1.75)

1.05 (0.62; 1.80)

1.05 (0.61; 1.79)

INPP5D (chr2) rs35349669 (T)

1.18 (0.70; 2.01)

1.18 (0.69; 2.01)

0.91 (0.51; 1.64)

0.93 (0.52; 1.66)

MEF2C (chr 5) rs190982 (G)
HLA-DRB5-DBR1 (chr 6) rs9271192 (C)

1.03 (0.64; 1.68)
1.13 (0.72; 1.78)

1.09 (0.67; 1.77)
1.14 (0.71; 1.82)

0.99 (0.58; 1.69)
0.61 (0.37; 1.02)

0.91 (0.53; 1.56)
0.62 (0.36; 1.04)

CD2AP (chr 6) rs10948363 (G)

1.30 (0.82; 2.07)

1.32 (0.82; 2.12)

1.09 (0.65; 1.82)

1.08 (0.64; 1.81)

NME8 (chr 7) rs2718058 (G)

1.11 (0.70; 1.77)

1.15 (0.72; 1.84)

0.79 (0.47; 1.33)

0.76 (0.45; 1.28)

ZCWPW1 (chr7) rs1476679 (C)
EPHA1 (chr7) rs11771145 (A)

0.57 (0.36; 0.91)
1.35 (0.84; 2.16)

0.57 (0.35; 0.90)*
1.44 (0.89; 2.34)

0.86 (0.52; 1.44)
0.84 (0.50; 1.44)

0.86 (0.51; 1.44)
0.92 (0.55; 1.55)

PTK2B (chr8) rs28834970 (C)

0.83 (0.51; 1.35)

0.86 (0.54; 1.39)

1.12 (0.66; 1.90)

1.14 (0.67; 1.93)

CLU (chr8) rs11136000 (T)

1.79 (1.07; 3.00)**

1.70 (1.01; 2.86)***

0.46 (0.25; 0.85)+

0.42 (0.23; 0.77)++

CELF1 (chr11) rs10838725 (C)
MS4A (chr11) rs983392 (G)

1.07 (0.67; 1.71)
1.35 (0.82; 2.21)

1.09 (0.68; 1.74)
1.35 (0.82; 2.22)

0.67 (0.39; 1.13)
0.62 (0.36; 1.09)

0.67 (0.40; 1.15)
0.61 (0.35; 1.07)

PICALM (chr11) rs10792832 (A)

1.42 (0.87; 2.30)

1.50 (0.92; 2.45)

1.22 (0.73; 2.05)

1.12 (0.66; 1.89)

SORL1 (chr11) rs11218343 (C)

0.67 (0.28; 1.62)

0.56 (0.24; 1.39)

0.63 (0.28; 1.41)

0.67 (0.30; 1.50)

FERMT2 (chr14) rs17125944 (C)

1.19 (0.65; 2.19)

1.19 (0.62; 2.26)

0.55 (0.29; 1.02)

0.57 (0.30; 1.07)

SLC24A4-RIN3 (chr14) rs10498633 (T)

1.30 (0.80; 2.09)

1.36 (0.84; 2.20)

0.67 (0.40; 1.12)

0.69 (0.41; 1.16)

ABCA7 (chr19) rs4147929 (A)

0.98 (0.60; 1.59)

0.99 (0.61; 1.61)

1.31 (0.76; 2.27)

1.27 (0.73; 2.20)

CD33 (chr19) rs12459419 (T)

1.00 (0.63; 1.57)

1.01 (0.64; 1.60)

1.35 (0.81; 2.25)

1.29 (0.78; 2.17)

Gene, (chromosome), SNP (effect allele)
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CASS4 (chr20) rs7274581 (C)
1.74 (0.95; 3.21)
1.76 (0.93; 3.34)
0.64 (0.32; 1.24)
0.70 (0.35; 1.38)
Odds ratios adjusted for sex, age at death, Pcs, Pcs=Principal components. *P = 0.0171, ** P= 0.0276, *** P=0.0457,
+P= 0.0131, ++P=0.0049; SNPs=Single nucleotide polymorphisms for Alzheimer’s Disease identified in the previous studies

CHAPTER FIVE
Conclusion
Summary
Despite an increase in research into the underlying pathology of
neurodegenerative diseases over the last few decades, there remains a lacuna in
understanding the complex nature of these diseases. There is an urgent need to find
methods to enhance preventive and treatment measures. Neurodegenerative diseases such
as AD, FTLD, Lewy body dementia, LATE, Parkinson’s disease, amyotrophic lateral
sclerosis, uncommon tauopathies result have aggregation of misfolded proteins or
proteinopathies in common, which is considered as neuropathological hallmarks of the
diseases.6 The Tau, Aβ, α-synuclein, and TDP-43 are the most commonly aggregated
proteins as pure proteinopathies or as mixed proteinopathies.
AD now known as a multifactorial disorder is characterized by progressive
dementia. It is the 6th leading cause of death in the U.S.28 The central pathology of AD
classically is defined by the accumulation of Aβ and tau tangles, however, the occurrence
of co-pathologies are now known to be common in older adults2,3,24,26,46,52,54,79,84,166 and
present as complex clinical presentations. Recent autopsy-based research studies have
assessed the presence of mixed proteinopathies and their influence on cognition during
life.3,5,24,26,44
The purpose of the study was to expand on the understanding of multiple
proteinopathies, their role in cognitive decline, in a community-based cohort study of
aging and dementia at the University of Kentucky Alzheimer’s Disease Center. The three
studies conducted: (1) “Prevalence and Clinical Phenotype of Quadruple Misfolded
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Proteins in Older Adults.” (2) “Four common late-life cognitive trajectories patterns
associate with replicable underlying neuropathologies.” (3) “Cancer history associates
with a lower burden of dementia and Alzheimer’s-type neuropathology in autopsied
research volunteers.” The major findings from these studies are summarized below:
Chapter Two described the frequency and associated characteristics of multiple
proteinopathies, focusing on quadruple misfolded proteins (QMP: Tau, Amyloid β, αSynuclein, TDP-43) among autopsied research volunteers. The proteinopathies were
categorized into seven case groups, among participants with at least misfolded tau. The
participants were included if they had data on all four proteins, which enabled us to carry
out detailed neuropathologic analyses. Some of the important findings of the study
revealed that mixed pathologies in our cohort were common rather than the exception.
Two proteinopathies were detected in 43% of cases, 38% had three, and 12% had the
QMP (i.e. presence of four proteinopathies) phenotype. The QMP pattern of copathologies was observed in 19.2% of demented subjects, equal to the prevalence of
“pure” AD pathology. Among pathology-defined groups, QMP subjects had the highest
dementia frequency (89.1%) and the lowest final mean (SD) MMSE scores (13.4 (9.8)).
Longitudinal assessments revealed that persons with eventual autopsy-confirmed QMP
traversed through MCI relatively quickly (1.7 years vs 2.9 years for pure AD). Further,
the association of proteinopathies with age at death, sex, education, and APOE ε 4 was
assessed. Adjusting for age at death and sex, the APOE ε4 was associated with higher
odds of QMP proteinopathy (AOR= 2.55; 95%CI, 1.16, 5.62; P = .02). To evaluate the
longitudinal association with global cognition, we used generalized estimating equations
to estimate the predicted probability of having mental status scores within normal
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(MMSE 27-30) or severely impaired (MMSE 0-13) ranges during the 12 years before
death. The QMP group had both the lowest probability of having normal MMSE, even 12
years before death and the highest probability of having severe impairment on the
MMSE. The presence of mixed pathologies (≥3) appears to play a major role in cognitive
decline.
In Chapter Three, the study focused on the patterns of longitudinal cognitive
status in older adults using the GBTM methods. The study was conducted using two
independent datasets of autopsied, longitudinally followed Alzheimer’s Disease Research
Centers’ participants (total N=1346). The GBTM models allow us to overcome
challenges in longitudinal analysis, that there are subgroups within the population that
follow distinctive trajectories over time.85,87 An extension to the GBTM method is the
GBMTM, using multiple variables in the same model, thereby there is 1:1
correspondence and the results are thus a cumulative group assignment across the
variables used in the model. Here we use longitudinal cognitive test scores of the
participants assessed longitudinally 10 years before death. The three test scores used here
are part of the cognitive tests conducted approximately annually during the clinical visit.
Cognitive test scores used were MMSE, Logical Memory Story A, and the Animal
Naming, representing global cognition, episodic memory, and verbal fluency
respectively. The GBMTM model identified four similar cognitive trajectories in both
cohorts. The trajectories determined by shape were labeled as “No Decline”, “Mild
Decline”, “Moderate Decline”, and “Accelerated Decline”. Furthermore, the predictors
and proteinopathies associated with the trajectories indicating cognitive status were
examined. The results showed the four trajectories showed distinctive patterns of
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cognitive function over a decade prior to death. In the Accelerated decline and Moderate
decline, participants showed an increased rate of decline with lower baseline test scores
and were more likely to be diagnosed with dementia before death. The Mild decline and
the No decline trajectory groups had initially similar test scores, but the decline rate
different in 4-5 years proximate to death. Analyzing the association of neuropathological
variables with the identified trajectory subgroups, the Accelerated decline group were
likely to die younger, were less likely to have higher education, have higher frequency
Braak NFT stage V/VI, TDP-43, and HS among UK-ADRC participants. While among
the NACC participants, the Accelerated decline group was additionally associated with αsynuclein and moderate to frequent arteriosclerosis. Other important findings of the study
are the relationship between each trajectory group and cognitive performance correlated
with both the number of proteinopathies and the burden of cerebrovascular pathology in
the brain. Additionally, the RF analysis allowed us to determine the importance of all the
variables of interest associated with trajectory groups. RF results suggested most
important trajectory predictors were the Braak NFT stage, cerebral atrophy, death age,
and brain weight.
In Chapter Four, we shifted our focus to the association of cancer and
neuropathology. Interestingly several prior studies have shown history that history of
cancer has an inverse association with clinical AD phenotype. In the current study, we
linked the autopsy data drawn from the UK-ADRC to the Kentucky Cancer Registry. The
goal of the study was to expand on the understanding of the causal association of history
of cancer and clinical diagnosis of dementia, AD-type pathology and to evaluate the
association of known single nucleotide polymorphisms associated with AD with cancer
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history and cognitive status. The statistical analyses involved the use of inverse
probability of treatment weights to account for confounding i.e., shared causes of cancer
and neuropathology. The results of the study confirm the inverse association of history
of cancer with MCI/Dementia diagnosis. The odds of having MCI/Dementia was lower
by 55% among the participants with cancer history. Participants with cancer history had
lower odds of Braak NFT stages III/IV, V/VI, Aβ plaques, and CAA.
Strengths and limitations
The dissertation primarily used UK-ADRC participant data, which is a
community-based longitudinal cohort with lengthy (mean of 8.8 ±5.6 years) follow-up.
The lengthy follow-up allowed us to examine the longitudinal cognitive performance of
the participants using different statistical methods. Another major strength is the
availability of well-characterized clinical diagnosis, multiple neuropathology measures,
and genetic data. Furthermore, subgroup analyses were conducted among participants
who were cognitively normal at baseline.
A limitation noteworthy is that UK-ADRC participants are not representative of
the general population of older adults in the U.S. Majority of participants were white,
well-educated, and thus generalizability of the results may be limited. Another limitation
is the limited sample size, a larger sample would be beneficial to examine intergroup
comparisons e.g. in chapter Four study we were unable to evaluate the cancer type,
staging, and treatment potentially relevant to aggregation of proteinopathies in the brain
as well as to the cognitive decline during life. The sample size also limited the
examination of effect modifications. The medical comorbidities in the UK-ADRC data
were self-reported and measured at baseline and hence could not be evaluated as time-
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varying variables. Furthermore, because of exclusion criteria used, as well as the rarity,
the burden of proteinopathies in rare dementia syndromes was not examined.
Future research
Several future research can be undertaken from the results of the dissertation.
First, we can extend the study to a more diverse and larger population to examine the
burden of proteinopathies. Some studies have reported that CVD pathology is more
prevalent in black79,80 and Hispanic80 individuals and are more likely to have mixed AD
pathology compared to white individuals. This is important as we are moving towards a
precision medicine approach, factors that can vary with ethnoracial groups may become
important in the management of neurodegenerative diseases. Furthermore, a larger
sample of cognitively normal at baseline may lead to a better understanding of the
cognitive performance of multiple proteinopathies.
Second, the GBMTM statistical analyses can be extended to other datasets using
cognitive test scores involving varied cognitive domains, which will give a better
discriminatory power to identify subgroups. Furthermore, the association of subgroups
with extended clinical classification subtypes can be examined, e.g. type of dementia
(AD dementia, vascular dementia, rare dementia syndromes, etc.). Third, genetic analysis
of proteinopathy groups would be useful in determining the lifetime risk of an individual.
It would be important to assess the genetic risks of individuals with multiple
proteinopathies vs those having fewer proteinopathies. The risk assessment may broaden
the understanding of multiple proteinopathies. Fourth, expand the association of cancer
data to examine the effect of cancer therapies on neuropathology accounting for timevarying medical comorbidities. An important issue is to understand the pathways of the
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inverse association of cancer history and AD pathology that may lead to finding adequate
treatment modalities for AD.
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